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Binding of GnRH to its receptor (GnRHR) stimulates the synthesis and secretion
of the gonadotropins, as well as up-regulation of GnRHR. Thus, the interaction between
GnRH and GnRHR represents a central point for regulation of reproduction.
Glucocorticoids alter reproduction by reducing GnRH responsiveness of gonadotropes
within the anterior pituitary gland, potentially via transcriptional regulation of the
GnRHR gene. Investigation into this mechanism, however, revealed that the murine
GnRHR gene was stimulated by glucocorticoids.

To determine the effect of

glucocorticoids on porcine GnRHR gene expression, gonadotrope-derived αT3-1 cells
were transiently transfected with a vector containing 5118 bp of 5’ flanking sequence for
the porcine GnRHR gene fused to luciferase for 12 h and treated with increasing
concentrations of the glucocorticoid agonist, dexamethasone (0, 1, 10, 100 and 1,000 nM)
for an additional 12 h prior to harvest. Maximal induction of luciferase activity was
detected at 100 nM of dexamethasone (2-fold over vehicle; P < 0.05). Deletion from 274
to 323 bp of proximal promoter eliminated glucocorticoid responsiveness, suggestive of a
glucocorticoid response element (GRE). Electrophoretic mobility shift assays (EMSAs)
using a radiolabeled oligonucleotide spanning -290/-270 bp of proximal promoter

revealed increased binding of nuclear extracts from αT3-1 cells treated with 100 nM
dexamethasone compared to vehicle. Mass spectrometry analysis of isolated proteins
from a pull-down using a biotinylated oligonucleotide (-290/-270 bp) identified PARP-1
as the binding component. EMSAs with either GR or PARP-1 antibodies resulted in a
supershift of the specific binding complex, whereas addition of both antibodies abolished
the supershift. Inhibition of p38 and ERK1/2 mitogen-activated protein kinase (MAPK)
pathways decreased dexamethasone-induced promoter activity (P < 0.05), indicating their
involvement in glucocorticoid stimulation of the promoter. Thus, our working model for
glucocorticoid responsiveness of the porcine GnRHR gene suggests that binding of
glucocorticoid to its receptor (GR), triggers GR phosophorylation by p38 and ERK1/2
MAPK pathways, resulting in the recruitment of PARP-1 by phosphorylated, ligandbound GR to a GRE located within -290/-270 bp of the porcine GnRHR promoter.
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CHAPTER I

INTRODUCTION

The decapeptide gonadotropin-releasing hormone (GnRH) is a key factor that
mediates the function of the hypothalamic-pituitary-gonadal axis in mammals. Generated
by hypothalamic neurons, GnRH is released in an intermittent manner, traveling to
gonadotropes in the anterior pituitary gland via the hypothalamo-hypophyseal portal
system (Fink, 1988). Gonadotropin-releasing hormone binds to high-affinity receptors on
gonadotrope cells resulting in the biosynthesis and secretion of both follicle stimulating
hormone (FSH) and luteinizing hormone (LH), which stimulate steroid synthesis and
gametogenesis in the gonads (Clayton and Catt, 1981; Clarke et al., 1983; Mason et al.,
1986).

Upon binding to its receptor, GnRH regulates expression of at least 4

gonadotropic genes including those encoding: the common α-glycoprotein subunit, the
specific LHβ- and FSHβ-subunits that combine to produce LH or FSH (Hamernik and
Nett, 1988; Gharib et al., 1990), and the GnRH receptor (GnRHR) itself (Sealfon and
Millar, 1995). Transcriptional regulation of GnRHR is mediated by GnRH via protein
kinase A (PKA) and C (PKC) activation of multiple mitogen-activated protein kinase
(MAPK) pathways including extracellular signal-regulated kinase (ERK), c-Jun Nterminal kinase (JNK), p38 MAPK, and ERK5, also known as big MAPK1 (BMK1;
Sundaresan et al., 1996; Roberson et al., 1999; Noar et al., 2000; Liu et al., 2003; Bonfil
et al., 2004). Thus, the interaction between GnRH and its receptor represents a central
point for regulation of reproductive function in mammals.
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Many studies have examined responsiveness of the GnRHR gene to hormones
including GnRH (White et al., 1999; Norwitz et al., 1999; Ellsworth et al., 2003; Liu et
al., 2003), estradiol-17β (Gregg et al., 1990; Laws et al., 1990b; Wu et al., 1994; Duval et
al., 2000), progesterone (Laws et al., 1990a; Cheng et al., 2001a), testosterone (Kaiser et
al., 1993; Curtin et al., 2001; Zapatero-Caballero et al., 2003) activin (FernandezVazquez et al., 1996; Pernasetti et al., 2001; Norwitz et al., 2002), and inhibin (Braden et
al., 1990; Gregg et al., 1991; Wu et al., 1994). Several reports indicated that GnRH
regulates GnRHR numbers and mRNA levels in the pituitary gland from the rat (Pieper et
al., 1982; Clayton, 1982; Kaiser et al., 1993; Bauer-Dantoin et al., 1995), sheep (Turzillo
et al., 1994), and cow (Vizcarra et al., 1997). In contrast, others reported no change in
amounts of GnRHR mRNA after GnRH treatment in the gonadotrope-derived αT3-1 cell
line (Tsutsumi et al., 1993, 1995; Alarid and Mellon, 1995). Besides regulation of the
level of GnRHR mRNA, GnRH can both up- and down-regulate receptor numbers in the
pituitary (McArdle et al., 1987; Uemura et al., 1992; Bauer-Dantoin et al., 1993; Conn et
al., 1995). Norwitz et al. (1999) determined two elements involved in GnRH
responsiveness, sequence underlying responsiveness to GnRH-1 and 2 (SURG-1 and
SURG-2, respectively) and Kam et al. (2005) reported that nuclear factor Y (NF-Y) and
octamer transcription factor-1 (Oct-1) bind to the SURG-1 element to increase basal and
GnRH-stimulated expression of the mouse GnRHR gene. White et al. (1999) isolated an
activation protein-1 (AP-1) element within SURG-2 that conferred GnRH responsiveness
of the GnRHR promoter. Moreover, these investigators identified that GnRH regulation
of the GnRHR gene was mediated via activation of an AP-1 element by PKC (White et
al., 1999) and the JNK pathway (Ellsworth et al., 2003). In addition, the GnRHR
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activating sequence (GRAS), important to basal promoter activity, also mediated activin
responsiveness of the mouse GnRHR gene (Duval et al., 1999). The binding of Smad3
and 4 proteins to GRAS (Duval et al., 2000) and AP-1 complexes to an overlapping AP-1
element regulated activin responsiveness (Ellsworth et al., 2003).

Further studies

demonstrated that binding of the LIM homeodomain proteins, LHX2 and 3, to a
downstream activin regulatory element (DARE) is also necessary for activin
responsiveness (Cherrington et al., 2005; Cherrington et al., 2006).
Reproductive function is suppressed under various stress conditions including
infection, malnutrition, restraint, strenuous exercise, and surgical trauma (Collu et al.,
1984; Rabin et al., 1988; Rivest and Rivier, 1995). Hormones that comprise components
of the HPA axis, such as CRH, arginine vasopressin, ACTH, and glucocorticoids have all
been shown to inhibit GnRH/gonadotropin secretion at the hypothalamic and/or pituitary
levels. CRH inhibits GnRH release in hypophyseal portal blood (Rabin et al., 1988) or
GnRH pulse generator activity (Williams et al., 1990). Arginine vasopressin and ACTH
are also reported to inhibit LH secretion by decreasing responsiveness of the pituitary to
GnRH as well as decreasing GnRH release (Dobson and Smith, 2000; Cates et al., 1999;
Mann et al., 1985).
Inhibitory effects of glucocorticoids on gonadotropin secretion have been well
documented in a variety of species, ranging from rodents to ruminants and primates,
including humans. Chronic or acute glucocorticoid treatment is reported to suppress LH
secretion in normal (nonstressed) animals or subjects (Baldwin, 1979; Saketos et al.,
1993; Breen et al., 2004). Thus, exogenous glucocorticoids injected into normal subjects
do inhibit LH secretion. The importance of the report by Matsuwaki et al. (2006) is that it
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elucidated the role of endogenous glucocorticoids released in response to stimuli induced
by stressors. The investigators found that glucocorticoids are protective rather than
inhibitory to LH secretion under stressful conditions. Their findings imply that there may
be substantial differences in the observed actions of exogenous glucocorticoids
administered into normal (nonstressed) subjects and endogenous glucocorticoids released
in stressed subjects. Previous reports by the same authors showed that glucocorticoids
counteract the suppressive effects of TNF-α, which mimics infectious stress, on both the
pulsatile (Matsuwaki et al., 2003) and surge (Matsuwaki et al., 2004) secretion of LH in
rats.

In support of their findings, two other reports demonstrated that endogenous

glucocorticoids did not mediate endotoxin-induced inhibition of pulsatile LH secretion in
rats (Watanobe and Habu, 2003) and sheep (Debus et al., 2002).

They show that

lipopolysaccharide suppresses LH pulses even in adrenalectomized rats and in sheep
treated with metyrapone, a glucocorticoid synthesis inhibitor.
Glucocorticoids can also act at both the hypothalamus and anterior pituitary gland
to regulate gonadotropin secretion (Brann and Mahesh, 1991; Tilbrook et al., 2000).
Recent investigations into stress-related influences on reproductive function implicated
glucocorticoids in the physiological regulation of GnRH and its receptors. For example,
glucocorticoids acted directly at the hypothalamus to suppress GnRH synthesis
(Chandran et al., 1994) and reduced the activity of the GnRH pulse-generating center
(Dubey and Plant, 1985).

Similarly, in the anterior pituitary gland, glucocorticoids

decreased GnRH responsiveness of gonadotrope cells (Kamel and Kubajak, 1987;
Baldwin et al., 1991). In contrast to inhibition of GnRH secretion from the hypothalamus
and reduced responsiveness of gonadotropes to GnRH, glucocorticoids also increased
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GnRHR mRNA and protein levels.

In male rats, the glucocorticoid agonist,

dexamethasone, acted directly on gonadotrope cells to modulate a GnRH-induced
increase in GnRHR numbers, as well as gonadotropin gene expression and secretion
(Rosen et al, 1991). In addition, dexamethasone treatment increased endogenous GnRHR
mRNA levels in the gonadotrope-derived LβT2 cell line (Turgeon et al., 1996) and
activity of the murine GnRHR promoter in pituitary adenoma-derived GGH3 (MayaNúñez and Conn, 2003) and LβT2 (McGillivray et al., 2007) cells. Maya-Núñez and
Conn (2003) identified the glucocorticoid response element (GRE) as an AP-1 binding
site located between 255 and 331 bp upstream of the transcriptional start site that bound
the transcription factor, c-Jun, suggesting that ligand-bound glucocorticoid receptors
interact directly or indirectly with c-Jun to regulate GnRHR transcription. Our laboratory
has isolated the porcine GnRHR gene promoter and identified elements conferring basal
activity in αT3-1 cells. The objectives of this study are to determine glucocorticoid
responsiveness of the porcine GnRHR gene, to isolate the glucocorticoid response
element(s) located within the porcine GnRHR promoter and to examine the molecular
mechanisms underlying glucocorticoid stimulation of GnRHR gene expression in αT3-1
cells.
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CHAPTER II

LITERATURE REVIEW

Characterization of Gonadotropin-Releasing Hormone

Function of Gonadotropin-releasing hormone
Gonadotropin-releasing hormone (GnRH) is a hypothalamic decapeptide that
plays a critical role in regulation of reproduction. It was first isolated from mammalian
hypothalami (Schally et al., 1971; Matsuo et al., 1971; Baba et al., 1971), and is
important for normal mammalian sexual maturation as well as reproductive function and
pregnancy (Bauer-Dantoin et al., 1993; Kaiser et al., 1997; Zapatero-Caballero et al.,
2003; Granger et al., 2004). GnRH is secreted from hypothalamic neurons in a pulsatile
manner every 30-120 minutes (Millar et al., 2004), travels through a portal system to the
anterior pituitary gland, and stimulates one of five cell types, gonadotropes, in the
anterior pituitary gland (Conn and Crowley, 1994; Carmel et al., 1976; Levine et al.,
1982). GnRH binds to its cognate receptor on the plasma membrane of gonadotrope cells
to stimulate the biosynthesis and release of the gonadotropins, luteinizing hormone (LH)
and follicle stimulating hormone (FSH; Figure 2.1). Upon binding to is receptor, GnRH
upregulates at least gonadotropic genes including: the common α-glycoprotein subunit,
specific LH and FSH β-subunits and the GnRHR itself (Gharib et al., 1990; Sealfon and
Millar, 1995). The common α-subunit then interacts with either LH or FSH β-subunits to
produce LH and
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Figure 2.1. Diagram of GnRH action on a gonadotrope cell. GnRH is secreted by
neurons in the hypothalamus and acts on gonadotrope cells of the anterior pituitary gland.
Binding of GnRH to its cognate receptor on the plasma membrane of the cell causes the
upregulation of genes encoding the common glycoprotein hormone α-subunit and
specific FSHβ- and LHβ-subunit genes, as well as the GnRHR itself.
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FSH, respectively (Clarke et al., 1983). Following synthesis and secretion of these
gonadotropins, they act on the gonads to function in reproduction. LH causes ovulation
in the female and promotes testosterone production in the male (Velardo, 1960; Veyssiere
et al., 1977).

FSH recruits follicle development in the female and stimulates

spermatogenesis in the male (Velardo, 1960; Weissenberg et al., 1982). In addition,
gonadotropins induced the production of androgens, progesterone and estradiol-17β.
These steroid hormones can negatively feedback at the level of the anterior pituitary and
the hypothalamus to regulate GnRH and gonadotropin secretion (Nakai et al., 1978;
McNeilly et al., 2003).

Therefore, the interaction between GnRH and its receptor

represents a central point for regulation of reproductive function in mammals.
In addition to its role in regulating reproduction, GnRH can also have diverse
functions in neuroendocrine, paracrine, autocrine and neurotransmitter/neuromodulatory
roles. Neuroendocrine functions have been shown in growth hormone release in certain
fish species, paracrine roles in placenta and gonads, autocrine actions in GnRH neurons,
immune cells, breast and prostatic cancer cells, and neurotransmitter/neuromodulatory
roles in the central and peripheral nervous system (Emons and Schally, 1994; Sherwood,
1987; Millar and King, 1987; Millar and King 1988; Jennes and Conn, 1994; Millar et al.,
2004; Millar, 2005; Kochman, 2012). It has been reported that GnRH peptides may
originally function in cellular communication in sexual reproduction of simple
organisms. Later, they were recruited to nerve cells to translate external and internal
signals into activation of reproduction, initially by acting directly on germ cells, and
subsequently via pituitary gonadotrope activation (Millar, 2005; Millar et al., 1987;
Hsueh and Schaeffer, 1985; Jennes and Conn, 1994)
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Structure of Gonadotropin-Releasing Hormone
Mammalian GnRH was first isolated from the ovine, bovine and porcine
hypothalamus (Kochman, 1966; Kochman 1969; Kochman and Domański, 1969), but its
characterization and primary structure were not known until Andrew V. Schally and
Roger Guillemin demonstrated them in 1971 (Matsuo et al., 1971; Burgus et al., 1972).
During subsequent years of intensive studies, 30 structurally different forms of GnRH
have been identified (Table 2.1). In vertebrates, 15 structural variants of the GnRH
molecule have been reported and 15 variants were found in invertebrates (Millar et al.,
2004; Roch et al., 2011).
The mammalian GnRH peptide consists of 10 amino acids which is pGlu-HisTrp-Ser-Tyr-Leu-Arg-Pro-Gly-NH2 (Schally et al., 1971). The N-terminal (pGlu-HisTrp-Ser) and C-terminal (Pro-Gly-NH2) sequences have been highly conserved for
approximately 600 million years of evolution (Millar et al., 2004; Millar, 2005), with the
exception of two cases of conservative Tyr substitutions (Table 2.1). These highly
conservative features are critically important for receptor binding and activation and
variations in positions 5, 7 and 8 are important for ligand selectivity (Millar et al., 2004;
Kochman, 2012). However, position 8 is the most variable amino acid and this variation
suggests that virtually any residue is tolerated in the position. Therefore, this residue may
play an important function in ligand-selectivity of the different GnRH receptors (Millar,
2005). It has been reported that these conserved NH2- and COOH-terminal groups are
closely apposed when mammalian GnRH binds its receptor, due to a β-II type turn
involving residues 5-8 (Figure 2.2; Sealfon et al., 1997; Karten and Rivier, 1986). This
conformational change results from intramolecular interactions with side chain of Arg in
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TABLE 2.1 AMINO ACID SEQUENCES OF NATURALLY OCCURRING GnRH
STRUCTURAL VARIANTS SPANNING APPROXIMATELY 500 MILLION YEAR
OF EVOLUTION
Amino acid sequence

1
2
3
4
5
6
7
8
9
10
11
12
13

Mammal*
Chicken I
Guinea Pig
Frog
Seabream
Salmon***
Medaka
Catfish
Whitefish
Herring
Dogfish
Lamprey II
Chicken II**

1
pGlu
pGlu
pGlu
pGlu
pGlu
pGlu
pGlu
pGlu
pGlu
pGlu
pGlu
pGlu
pGlu

2
His
His
Tyr
His
His
His
His
His
His
His
His
His
His

3
Trp
Trp
Tyr
Trp
Trp
Trp
Trp
Trp
Trp
Trp
Trp
Trp
Trp

4
Ser
Ser
Ser
Ser
Ser
Ser
Ser
Ser
Ser
Ser
Ser
Ser
Ser

5
Tyr
Tyr
Tyr
Tyr
Tyr
Tyr
Phe
His
Tyr
His
His
His
His

6
Gly
Gly
Gly
Gly
Gly
Gly
Gly
Gly
Gly
Gly
Gly
Gly
Gly

7
8
Leu Arg
Leu Gln
Val Arg
Leu Trp
Leu Ser
Trp Leu
Leu Ser
Leu Asn
Met Asn
Leu Ser
Trp Leu
Trp Phe
Trp Tyr

9
Pro
Pro
Pro
Pro
Pro
Pro
Pro
Pro
Pro
Pro
Pro
Pro
Pro

10
Gly
Gly
Gly
Gly
Gly
Gly
Gly
Gly
Gly
Gly
Gly
Gly
Gly

NH2
NH2
NH2
NH2
NH2
NH2
NH2
NH2
NH2
NH2
NH2
NH2
NH2

Gly
Glu

Trp
Trp

Pro
Pro

Gly
Gly

NH2
NH2

Pro
Pro
Pro
Pro
Pro
Pro
Pro
Pro
Pro

Gly
Gly
Gly
Gly
Gly
Gly
Gly
Gly
Gly

NH2
NH2
NH2
NH2
NH2
NH2
NH2
NH2
NH2

11 12
Pro Gly
Pro Gly
Ala Ser Pro Pro -

NH2
NH2
NH2
NH2
NH2
NH2

14 Lamprey III
15 Lamprey I

pGlu His Trp
pGlu His Tyr

Ser His
Ser Leu

16
17
18
19
20
21
22
23
24

Chelyosoma I
Chelyosoma II
Ciona I
Ciona II
Ciona III
Ciona IV
Ciona V
Ciona VI
Ciona VII

pGlu
pGlu
pGlu
pGlu
pGlu
pGlu
pGlu
pGlu
pGlu

His
His
His
His
His
His
His
His
His

Trp
Trp
Trp
Trp
Trp
Trp
Trp
Trp
Trp

Ser
Ser
Ser
Ser
Ser
Ser
Ser
Ser
Ser

25
26
27
28
29
30

Octopus
Sea Urchin
Aplysia
Limpet
Marine worm
Leech

1
pGlu
pGlu
pGlu
pGlu
pGlu
pGlu

2
Asn
Val
Asn
His
Ala
Ser

3
Tyr
His
Tyr
Tyr
Tyr
Ile

4
His
His
His
His
His
His

Asp
Leu
Tyr
Leu
Asn
Tyr
Tyr
Lys
Asn

Lys
Lys

Tyr Phe Lys
Cys His Ala
Ala Leu Ser
Ala Leu Ser
Gln Leu Thr
Glu Phe Met
Glu Tyr
Met
Gly Tyr
Ser
Lys Leu
Ala

5
6
7
Phe Ser Asn
Arg Phe Ser
Phe Ser Asn
Phe Ser Asn
Phe Ser His
Phe Ser Asn

8
Gly
Gly
Gly
Gly
Gly
Ser

9
Trp
Trp
Trp
Trp
Trp
Trp

10
His
Arg
Tyr
Lys
Phe
Gln

* mammal - mammalian GnRH; mGnRH:GnRH I
** chicken II - cGnRH II : GnRH II
*** salmon GnRH - sGnRH : GnRH III
† The encircled amino acid residues (on the left and on the right) show the conserved NH 2- and
COOH-terminal residues that play important functional roles. Non-conserved residues are
either unimportant or convey ligand selectivity for a particular GnRH receptor. The GnRHs
are named according to the species in which they were first discovered, and they may be
represented in more than one species. Adapted from Kochman (2012).
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Figure 2.2. Schematic presentation of mammalian GnRH in the folded conformation in
which it is bound to the GnRH receptor. The molecule is bent around the flexible glycine
in position six. Substitution with D-amino acids in this position stabilizes the folded
conformation, increases binding affinity, and decreases metabolic clearance. This feature
is incorporated in all agonist and antagonist analogues. The NH2 and COOH termini are
involved in receptor binding. The NH2 terminus alone is involved in receptor activation
and substitutions in this region produce antagonists. Adapted from Millar (2005)
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position 8 (Milton et al., 1983; Guarnieri and Weinstein, 1996). In addition, substitution
of Arg caused a more extended form with a loss of a specific tertiary structure and a low
binding affinity for its receptor (Maliekal et al., 1997). These extended forms, however,
showed high activity in non-mammalian GnRH receptors (Sealfon et al., 1997; Illing et
al., 1999; Tensen et al., 1997), whereas they exhibited low activity at mammalian
receptors (Flanagan et al., 1994; Fromme et al., 2001).

Characterization of Gonadotropin-Releasing Hormone Receptor

Amino Acid Sequences of Gonadotropin-Releasing Hormone Receptor
The amino acid sequence of the GnRH receptor (GnRHR) was established first
for the mouse receptor cloned from the murine gonadotrope-derived cell line, αT3-1,
utilizing a PCR-based homology cloning strategy (Windle et al., 1990; Sealfon et al.,
1990; Tsutsumi et al, 1992) and was subsequently confirmed using Xenopus oocyte and
mammalian cell line expression cloning (Reinhart et al., 1992; Perrin et al., 1993). This
sequence provided the basis for cloning of additional homologous pituitary cDNAs in
other mammalian species including the human (Kakar et al., 1992; Chi et al., 1993), rat
(Eidne et al., 1992; Kaiser et al., 1992; Perrin et al., 1993), sheep (Brooks et al., 1993;
Illing et al., 1993), cow (Kakar et al., 1993) and pig (Weesner and Matteri, 1994). An
alignment of the cloned GnRHR sequences is shown in Figure 2.3. This sequence
alignment shows more than 85% conserved homology overall and is nearly identical
within the putative transmembrane domains (Sealfon et al., 1997; Cheng and Leung,
2000). Also, this alignment revealed that the cow, sheep, pig and human receptors have
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Figure 2.3. Sequence alignment of cloned GnRH receptors. The putative transmembrane
domains are indicated. m, Murine; r, rat; h, human; o, ovine; b, bovine; p, pig; cf, catfish.
The consensus sequence reflects the mammalian sequences only. The junctions between
exons in the murine and human receptors are indicated by **. Adapted from Sealfon
(1997).
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one more amino acid compared to the mouse and rat receptors (327 amino acid residues),
due to the absence of one residue in the second extracellular domain (Kochman, 2012;
Cheng and Leung, 2000; Millar, 2005).

Unlike the mammalian receptors, non-

mammalian receptors have only 58 – 68% identity among each other and those with the
greatest homology to mammalian pituitary receptors have at most 42 – 47% amino acid
identity (Millar, 2005; Millar et al., 2004; Kochman, 2012).

Structure of Gonadotropin-Releasing Hormone Receptor
The GnRHR is a member of the rhodopsin-like, G protein-coupled receptor
(GPCR) family which contains seven transmembrane (TM) domains (Stojilkovic et al.,
1994; Sealfon et al., 1997; Cui et al., 2000). The NH2-terminal group is followed by
seven putative, α-helical TM domains connected by three extracellular loop and three
intracellular loop domains (Figure 2.4; Kakar et al., 2002; Neill, 2002; Millar, 2005).
The extracellular and superficial regions of the TMs are usually important for
conformational change during receptor activation following ligand binding, whereas the
intracellular domains are involved in interacting with G-proteins and other proteins
associated with intracellular transduction (Millar, 2005; Kakar et al., 2002).
Unlike other members of the GPCR family, GnRHRs do not have an intracellular
C-terminal domain which is required for desensitization and internalization of many
GPCRs (Conn et al., 1995; Kakar et al., 1992; Tsutsumi et al., 1992; Stojilkovic et al.,
1994). In most GPCRs, the C-terminus contains several phosphorylation sites that are
involved in ligand binding and play an important role in receptor desensitization
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Figure 2.4. Two-dimensional representation of the human GnRH receptor showing
amino acids conserved between cloned vertebrate GnRH receptors (yellow) and
conservative substitutions (blue). Putative ligand binding sites and residues important
in receptor configuration, activation and G-protein coupling are indicated.
Glycosylation, phosphorylation and disulphide bridge sites are also shown. Adapted
from Millar (2005).
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and internalization (Leeb-Lundberg et al., 1987; Sibley et al., 1987). For example,
removal of the C-terminal domain decreased the rate of internalization of thyrotropinreleasing hormone receptor (Nussenzveig et al., 1993), diminished agonist-induced
internalization of gastrin-releasing peptide (Benya et al., 1993), lost internalization and
endocytosis of the angiotensin type I receptor (Hunyady et al., 1994; Thomas et al., 1995)
and delayed desensitization and sequestration of the LH, α-1B-adrenergic and βadrenergic receptors (Lattion et al., 1994; Strader et al., 1987; Zhu et al., 1993). In αT3
cells, GnRH stimulated the accumulation of [3H]-thymidine for at least 90 min (Davidson
et al., 1994b) and increased the levels of inositol triphosphate (IP3) for at least 5 min
(Anderson et al., 1995; McArdle et al., 1996; Merelli et al., 1992), suggesting that the
GnRHR does not undergo rapid desensitization in αT3 cells due to the lack of C-terminal
tail and the phosphorylation sites necessary for agonist-dependent desensitization (Kakar
et al., 2004).
In addition, the GnRHR contains five potential phosphorylation sites in the
intracellular loops. Willars et al. (1998) reported that these sites are not involved in
agonist-dependent phosphorylation, suggesting the phosphorylation sites present in the
intracellular loops may not be important for desensitization of the receptor. The GnRHR
also possesses potential protein kinase C (PKC), phospholipase C (PLC) and cAMPdependent protein kinase A (PKA) phosphorylation sites in the intracellular loops. One
PKC phosphorylation site is located in the first intracellular loop, whereas three potential
PLC sites and one potential PKA site are present in the third intracellular loop (Kakar et
al., 2004). Cassina et al. (1999) demonstrated that both PKC and PKA phosphorylated
synthetic peptides for the three intracellular loops in vitro. Consistent with this, they
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showed that treatment of rat pituitary cell cultures in combination with phorbol 12myristate 13-acetate (PMA) and cholera toxin reduced LH secretion, whereas individual
treatment of PMA and cholera toxin had no effect on LH secretion, suggesting that more
than one signaling pathway is required to induce GnRHR desensitization. Mutation of all
the potential PKC phosphorylation sites (Thr238, Ser253, and Thr264) in the third
intracellular loop to Ala abolished the binding affinity of the receptor and reduced IP 3
production (Lin et al., 1998; Ulloa-Aguirre et al., 1998), whereas mutation of only Ser253
and Thr264 to Ala did not alter ligand binding or IP3 production. However, ligand binding
affinity (Ulloa-Aguirre et al., 1998) and receptor-mediated signal transduction (Lin et al.,
1998) were decreased when the C-terminal domain of the third intracellular loop was
deleted. Collectively, this evidence indicated that residues in the C-terminal domain of
the third intracellular loop, including the PKC phosphorylation sites, are important for the
structural integrity, expression, and signal transduction of the GnRHR.

Tissue Expression of Gonadotropin-Releasing Hormone Receptor
In general, GnRHRs are expressed only on the plasma membrane of gonadotropes
to control reproductive function (Clayton and Catt, 1981; Childs and Unabia, 1997).
Rodents are an exception with in that GnRHRs are also present in the gonads (Kakar et
al., 1992).

However, other tissues bind [125I]-labled GnRH agonists, suggestive of

GnRHR expression. Early studies described that the binding affinities of GnRH to
extrapituitary tissues measured using radioreceptor assays were significantly lower than
those of the receptor on gonadotropes of the anterior pituitary (Bramley et al., 1986;
Eidne et al., 1985; Emons et al., 1989; Vincze et al., 1991). These include specific nuclei

18
in the central nervous system (Jennes et al., 1997), human placenta (Wolfahrt et al.,
1998), somatotropes (Leibow et al., 1991), and various tumors of the pituitary and
pancreas (Emons et al., 1998).

In addition, the discovery of more potent GnRH

analogues allowed the identification of high affinity binding sites in various hormoneresponsive human tumors (breast and prostate) as well as cells derived from breast,
prostate, liver, uterine endometrium, and ovarian tumors (Chen et al., 1992; Emons et al.,
1993; Emons and Schally, 1994; Irmer et al., 1995; Segal-Abramson et al., 1992; Yano et
al., 1994).
In the ovary, granulosa-luteal cells express GnRHR mRNAs and mRNA levels
increase with follicular growth and development (Peng et al., 1994). GnRHR binding has
been demonstrated in luteinized granulosa cells, late antral follicles and developing
corpora lutea, but not in primordial, early antral and preovulatory follicles (Brus et al.,
1997; Choi et al., 2006). This stage-specific expression of GnRHR in human granulosa
and luteal cells suggests a role for GnRH in the regulation of ovarian physiology (Cheung
and Wong, 2008). GnRHR protein and mRNA have also been found in human ovarian
tumors, ovarian cancer cell lines and their tissue of origin, ovarian surface epithelium
(Choi et al., 2001; Emons et al., 1989).

Interestingly, GnRHR levels in ovarian

carcinomas are increased in advanced (stages III and IV) compared to early (stages I and
II) stages (Chien et al., 2004).
In addition to the ovary, GnRHR has been found in testicular germ cells of the rat
and mouse (Bull et al., 2000) and receptor binding studies with GnRH agonists revealed
the presence of GnRHR on Leydig cells of human testicular tissue (Clayton et al., 1980;
Lefebvre et al., 1980). Later, the mRNA sequence of these testicular receptors was
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determined to be identical to those on gonadotrope cells of the anterior pituitary (Botte et
al., 1998). However, GnRHR mRNA levels were decreased by direct binding of GnRH
analogs to testicular GnRHRs (Botte et al., 1999), suggesting that specific GnRHRs on
Leydig cells were important in the physiological regulation of testicular function and the
anti-fertility effects of GnRH agonists within the testis (Lefebvre et al., 1980).
The human placenta also had specific binding sites for GnRH that interacted with
GnRH agonists and antagonists (Iwashita et al., 1986) and were localized to
cytotrophoblast and syncytiotrophoblast cell layers of the placenta (Casan et al., 1999;
Boyle et al., 1998). This placenta GnRHR was structurally and biochemically identical to
pituitary GnRHRs, although GnRH binding affinity was lower (Escher et al., 1988;
Bramley et al., 1992). During pregnancy, GnRHRs are dynamically dispersed (Cheng et
al., 2001) and temporal expression of GnRHRs in placental cells has been observed at
different weeks of gestation, along with chorionic gonadotropin secretion level (Lin et al.,
1995).
Although GnRHRs have been isolated in breast tissue (Casan et al., 1998), its
expression was questioned due to a small sample size (Kottler et al., 1997). However,
others immunolocalized the GnRHR to the cytoplasm of human breast cancer cell lines
and tumor biopsy specimens (Kottler et al., 1997; Moriya et al., 2001; Eidne et al., 1987).
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Signal Transduction Mechanisms of the Mammalian GnRH Receptor

Receptor Activation
GnRH activation of signaling pathways is initiated by a change in receptor
conformation and propagated by intracellular pathways within the cell (Kenakin, 1993).
For GPCRs, the active conformation is related to a ternary complex consisting of
hormone, receptor and G-protein (De Lean et al., 1980). This ternary complex develops
an initial binding step common to both agonists and antagonists, followed by a transition
step, exclusive to agonists, which leads to formation of the ternary complex. The model
also allows for spontaneous formation of a receptor-G-protein complex, which has a
higher affinity for agonists and is stabilized via binding of agonists. When GTP binds to
the G-protein, the receptor returns to the low affinity conformation and the complex
dissociates (De Lean et al., 1980). There are a number of different GnRHR active
conformations that are selective for GnRH analogues and intracellular signaling pathways
(Millar and Pawson, 2004).

G-Protein Coupling
GPCRs transmit their signals primarily via GTP-binding proteins (G-proteins),
which are heterotrimeric proteins composed of an α subunit (Gα) that binds guanine
nucleotides, and a dimer that consists of a β and γ subunit (Gβγ). Upon stimulation, Gα
dissociates from the Gβγ dimer rendering to its active GTP-bound form to influence
effector molecules. The βγ dimer remains attached to the plasma membrane and can
initiate several signaling events (Kraus et al., 2001). G-proteins can be classified into the
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four following groups: Gαs, Gαi, Gαq/11, and Gα12/13. Gαs mainly activates adenylate
cyclase, which induces the production of high levels of the second messenger cAMP.
Unlike Gαs, the Gαi protein has inhibitory effects on adenylate cyclase (Birnbaumer,
1992).

Gαq/11 principally exerts its action by activating membrane-associated

phospholipase C (Hsieh and Martin, 1992), whereas Gα12/13 primarily operates by
stimulation of protein tyrosine kinases (PTKs; Jiang et al., 1998).
The nature of G-protein coupled signaling initiated by the GnRHR depends
largely on the cellular context (Figure 2.5). For example, it has been demonstrated that
the human GnRHR couples to Gαq/11 in heterologous Chinese hamster ovary-K1 and
COS-7 cells (Grosse et al., 2000) but to Gαs in the placenta (Cheng et al., 2000). In
contrast, others reported that the receptor couples selectively to Gαi in some reproductive
tract tumors and cell lines derived from them (Emons et al., 1998; Grundker et al., 2001;
Limonta et al., 1999; Imai et al, 1996). Interestingly, the rodent GnRHR couples to
multiple G-proteins in LβT2 (Liu et al., 2002), GGH3 (Stanislaus et al., 1998), and GT1-7
(Krsmanovic et al., 2003) cells.

In GT1-7 neurons, elevated GnRH analogue

concentrations induced a ligand-dependent switch of G-protein coupling from Gαs to Gαi,
which inhibits episodic GnRH release (Krsmanovic et al., 2003). Such negative feedback
action serves as an autocrine mechanism for pulsatile GnRH secretion that is essential for
the maintenance of normal gonadotropin release profiles and gonadal function (Cheng
and Leung, 2005).
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Figure 2.5. Signal transduction cascades activated by GnRH within gonadotrope cells.
Upon binding of GnRH to GnRHR, intracellular signaling pathways are triggered via
PKA and/or PKC. Following activation of PKC, a variety of MAPK pathways including
JNK, ERK, or p38 MAPK can be activated.
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Activation of Protein Kinase A or Protein Kinase C
Protein Kinase A. Regulation of the GnRHR by GnRH occurs via two major
signal transduction pathways, activation of protein kinase A (PKA) or protein kinase C
(PKC). In the PKA pathway, GnRHR is coupled to the Gαs protein (Figure 2.5). Upon
binding of GnRH to its receptor, the receptor is activated by a conformational change
allowing dissociation of the Gαs protein from Gβ and Gγ protein subunits. Gαs
consequently activates adenylate cyclase, which converts adenosine triphosphate (ATP)
to cAMP (Figure 2.5). Following production of increased amounts of cAMP, cAMP
activates PKA (Figure 2.5), resulting in phosphorylation of a variety of other downstream
signaling cascade proteins within the cell (Naor et al., 2000; Millar et al., 2004).
In rat pituitary cell cultures, GnRH stimulated cAMP production (Hawes et al.,
1993).

Furthermore, GnRH agonist-induced release of cAMP occurred in

somatolactotropes over-expressing the rat GnRHR (GH3; Kuphal et al, 1994),
baculovirus-insect cells (sf9; Delahaye et al. 1997), monkey kidney COS-7 cells overexpressing the human GnRHR (Arora et al., 1998) and Chinese hamster ovary (CHO;
Nelson et al., 1999) cells. In αT3-1 cells, treatment with 8-bromo-cAMP and forskolin
stimulated GnRHR mRNA levels (Sadie et al., 2003). Additional studies indicated that
GnRH utilizes the PKA signaling pathway to stimulate its target cells. For instance,
treatment of both pituitary and αT3-1 cells with pituitary adenylate cyclase-activating
polypeptide (PACAP) resulted in increased α-subunit mRNA levels (Tsujii et al., 1995).
However, White et al. (1999) reported that forskolin treatment completely blocked
GnRH-stimulated GnRHR promoter activity. Similarly, Norwitz et al. (1999) found that
the major signaling pathway in αT3-1cells that confers GnRH responsiveness of the
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mouse and human GnRHR gene promoters is the PKC, and not the PKA pathway. These
results indicates that, although GnRHR may not be directly regulated via the PKA
signaling pathway, the receptor can be regulated in response to other signaling molecules
that activate the PKA pathway.

Protein Kinase C. In αT3-1 cells, binding of GnRH to its heptahelical receptor
leads to the stimulation of Gαq/11 protein (Shah and Milligan, 1994) and activation of
phospholipase Cβ1 (PLCβ1; Naor, 1990) followed by enhanced phosphoinositide
turnover to inositol 1,4,5-triphosphate (IP3), production of diacylglycerol (DAG), and
activation of various PKC subspecies (Harries et al., 1997). Pituitary cells particularly
express PKCδ and PKCε, but also atypical PKCs, which are DAG- and Ca2+-independent
(Harries et al., 1997). Generation of IP3 leads to an initial rapid rise in intracellular Ca2+
concentration resulting from release of intracellular Ca2+ stores. DAG leads to activation
of PKC isozymes and contributes to a more sustained rise in intracellular Ca2+ through Ltype voltage gated channels (Benard et al., 2001).
Ca2+ is an important intracellular messenger that regulates diverse physiological
processes. For example, treatment of pituitary cells with the Ca2+ ionophore ionomycin
resulted in a significant stimulation of GnRH secretion (Stojilkovic et al., 1994;
Stojilkovic et al., 1995; Trueta et al., 1999). GnRH induces immediate intracellular Ca2+
mobilization followed by extracellular Ca2+ influx. These GnRH-induced Ca2+
oscillations occur through mobilization of two distinct calcium pools (Stojilkovic et al.,
1994; Iida et al., 1991). Extracellular Ca2+ enters the cell through voltage-gated calcium
channels in the plasma membrane, while IP3 releases Ca2+ from intracellular stores. The
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release of Ca2+ from intracellular stores is an important trigger for secretion in many
cells. In the case of GnRH, both intracellular and extracellular Ca2+ were shown to be
involved in the secretion of LH and FSH (Stojilkovic et al., 1994; Naor, 1990; Stojilkovic
et al., 1995). However, the IP3-released calcium seems to be critical for gonadotropin
secretion, whereas Ca2+ influx through the plasma membrane is mainly required for the
renewal of internal stores (Tse et al., 1997). Therefore, activation of PKC and increased
Ca2+ concentrations are among the important events that mediate GnRH action in
pituitary cells. Furthermore, these events are prerequisite for activation of mitogenactivated protein kinase (MAPK) activity, in particular the extracellular signal-regulated
kinase (ERK) pathway (Mulvaney and Roberson, 2000).

Activation of Mitogen-Activated Protein Kinase
The MAPK pathways are highly conserved signal transduction cascades that
mediate cellular responses to a large variety of environmental stimuli (Bliss et al., 2010).
In mammals, there are 4 predominant MAPK pathways: the ERK, jun-N-terminal kinase
(JNK), p38, and ERK5/Big MAP kinase (ERK5/BMK) pathways. Activation of the
pathway begins with phosphorylation of an upstream MAP kinase-kinase kinase
(MAPKKK), which phosphorylates and activates an intermediate level MAP kinase
kinase (MAPKK). The MAPKK in turn activates and the terminal MAP kinase (MAPK).
In addition to these core kinases, numerous scaffolding and adaptor proteins play
important roles in this pathway (Morrison and Davis, 2003).

Activated MAPKs

phosphorylate numerous substrates throughout the cell including those involved with
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transcriptional machinery, chromatic components, cytoskeletal structures, and other
downstream enzymes (Pearson et al., 2001; Yoon and Seger, 2006).
In pituitary-derived cells, GnRH activated all four MAPK cascades to various
extents by a PKC- and tyrosine-kinase dependent mechanism (Naor et al., 2000). In αT31 cells, GnRH activated the JNK pathway by approximately 20-fold (Levi et al., 1998).
Activation of JNK was transient, peaking at 30 min and declining thereafter. Similarly,
the ERKs were also activated (~12-fold), ERK phosphorylation was detected 2 min after
GnRH treatment, peaked at 7 min, and decreased to basal levels within 60 min (Benard et
al., 2001). On the other hand, the remaining two MAPKs, p38 MAPK and BMK1, were
only slightly activated (2 to 3-fold) in a transient manner, peaking 30 min after
stimulation (Roberson et al., 1999).

However, the mechanism underlying MAPK

activation is significantly varied among systems. For example, in GGH3 cells, ERK
activity is mediated by both PKA and PKC (Han and Conn, 1999). In Caov-3 cells,
GnRHR signals either through Gα or the dissociated Gβγ dimer, whereas in LβT2 cells,
JNK activation by GnRH is not dependent on PKC (Yokoi et al., 2000).
Activation of ERKs by GnRH has been widely studied (Sim et al., 1993; Mitchell
et al., 1994; Roberson et al., 1995).

Alterations in GnRH pulse pattern affect the

responsiveness of ERKs to GnRH (Haisenleder et al., 1998). Continuous exposure of
αT3-1 cells to GnRH stimulated short-term (2 h) ERK activity, whereas pulsatile GnRH
stimulated ERK activity for at least 8 h. Thus, GnRH pulses are required to maintain and
prolong activation of ERKs. In similar manner, TPA (a PKC activator) caused a 2 h
stimulation of ERKs, whereas EGF induced a much shorter effect (Reiss et al., 1997).
The similar time-course obtained with GnRH and TPA indicated that PKC may be
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involved in the activation of ERKs by GnRH in αT3-1 cells. PKC depletion results in
marked inhibition of the GnRH response (Reiss et al., 1997) and the PKC inhibitor
GF109203X abolishes GnRH-induced ERK activation (Benard et al., 2001). Therefore,
ERK activation by GnRH in pituitary cells is mainly PKC-dependent (Kraus et al., 2001).
Activation of ERKs by GnRH in αT3-1 cells involves two distinct signaling pathways
that converge at the level of Raf1 (Benard et al., 2001). The main pathway involves
direct activation of Raf1 by PKC, whereas the second, supportive pathway involves
activation of Ras in a c-Src- and dynamin-dependent manner (Benard et al., 2001).
Pretreatment with the PKC inhibitor GF109203X abolished GnRH-induced ERK
activation, whereas the PTK inhibitor, genistein, and the c-Src inhibitor, PP1, only
partially inhibited by ~40%, respectively. In addition, co-overexpression with the Cterminal Src kinase (CSK), which acts as a dominant-negative interfering mutant of cSrc, and with the dominant negative form of Ras had a partial inhibitory effect by 35% on
the GnRH to ERK pathway (Benard et al., 2001). Dynamin appears important for the
GnRH to ERK pathway because its dominant-negative form inhibited activation of Ras in
a PKC-independent manner.
Ca2+ is a critical mediator of the induction of gonadotropin secretion by GnRH.
Removal of Ca2+ markedly reduced ERK activation by GnRH (Reiss et al., 1997) and
calcium influx through voltage-gated calcium channels (VGCCs) is absolutely required
for activation of ERKs by GnRH in both αT3-1 and primary cultured pituitary cells
(Mulvaney and Roberson, 2000). Treatment of ells with the PKC inhibitor staurosporine
blocks the GnRH-induced VGCC signal, indicating that Ca2+ operates downstream of
PKC in the pathway that leads to ERK activation. Similar dependency on PKC and Ca 2+
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was also demonstrated in LβT2 cells (Yokoi et al., 2000), indicating that ERK activation
by GnRH in pituitary cells is strongly dependent upon DAG-sensitive PKC isozymes and
requires Ca2+.
The JNK signaling cascade is also the main MAPK pathway involved in GnRH
signaling in αT3-1 cells. JNKs ate activated 20 to 50-fold by GnRH and by TPA in αT31 cells (Levi et al., 1998). Time-course of JNK activation in response to GnRH is slower
than that of ERK activation, indicating that regulation of JNK activation by GnRH is
different from that of ERK. Levi et al. (1998) also showed that activation of JNKs is
both PKC- and PTK-dependent. However, PTK inhibitors completely abolished GnRHinduced JNK activation, but depletion of PKC or the use of PKC inhibitors prevented
only ~70% of GnRH-JNK signals, indicating the existence of a PKC-independent
signaling component. They found that GnRH as well as TPA also increased the activity
of c-Src. Coexpression of CSK and constitutively active forms of c-Src, together with
JNK1, confirmed the involvement of c-Src downstream of PKC in the GnRH-JNK1
pathway. They further demonstrated that c-Src together with the small GTPase CDC42
(and possibly Rac) and MEKK1 are the main mediators of the GnRH-JNK1 pathway.
Collectively, GnRH stimulates JNKs activity by a pathway that includes sequential
activation of PKC, c-Src, CDC42 (Rac), and MEKK1.
MAPKs play a role in the regulation of gene expression in various systems, either
by activating nuclear transcription factors directly or by phosphorylating downstream
cytoplasmic protein kinases. For example, ERK phosphorylates the ternary complex
factor Elk1, a member of the Ets family of transcription factors (Marais et al., 1993).
Elk1 has been shown to bind to the GnRH-responsive element located within the α-
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subunit gene promoter region, and GnRH increases promoter activity in αT3-1 cells
(Roberson et al., 1995). In αT3-1 cells, ERK is translocated into the nucleus within 2030 min of GnRH stimulation and this nuclear translocation supports a role for ERKs in
transcriptional regulation of gonadotropin subunit genes (Kraus et al., 2001; Roberson et
al., 1995; Haisenleder et al., 1998). Moreover, the MEK inhibitor PD098059 was shown
to block GnRH-stimulated mRNA accumulation of the α-subunit and FSHβ in GnRH via
ERK-, PKA, and Ca2+- dependent pathways (Lin and Conn, 1999).
JNKs were also shown in many systems to translocate into the nucleus upon
stimulation to phosphorylate and activate transcription factors such as c-Jun, ATF2, Elk1,
and p53. Levi et al. (1998) reported that the delayed response of JNKs observed in their
experiments may indicate that JNKs are involved in a later stage of transcriptional
regulation. Activation of JNKs and ERKs provides a route for activation of c-jun and cfos, respectively to form the jun-fos dimer that might activate the activator protein-1 (AP1) responsive element present in both LHβ and FSHβ promoter (Hirai et al., 1990).
Strahl et al., (1998) also showed that GnRH induces FSHβ gene expression via activation
of the AP-1 element. Although GnRH induction and basal control of the α-subunit gene
appear to occur through the ERK pathway, induction of the LHβ gene is dependent on
JNKs, suggesting the differential stimulation of transcription of LH subunit genes by
GnRH (Kraus et al., 2001). Yokoi et al., (2000) has shown that the JNK cascade is
necessary to elicit the LHβ promoter in a c-Jun-dependent mechanism in LβT2 cells. In
addition, it was reported that the common α-subunit gene is regulated by c-Jun and ATF2
at the cAMP-responsive element (CRE) site and by Elk1 at the Ets site of the pituitary
glycoprotein hormone basal element (PGBE) domain (Roberson et al., 1999; Heckert et
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al., 1996). Therefore, it is likely that the MAPK cascades play a role in the expression of
α- and β-subunits of gonadotropin genes.

Transcriptional Regulation of GnRHR by Hormone

Basal Expression of GnRHR Gene
The 5′ flanking regions of GnRH I genes have been characterized in the mouse
(Albarracin et al., 1994), rat (Reinhart et al., 1997), human (Fan et al., 1995; Kakar,
1997) and sheep (Campion et al., 1996). The mouse and rat promoters share > 80%
homology over 1.9 kb. However, the rat promoter shares 55% homology with the human
promoter over 2.2 kb and 63% homology with the sheep promoter over 0.9 kb (Pincas et
al., 1998). There are several highly homologous regions within the proximal 500 bp of
the mouse, rat, human and sheep promoters (Pincas et al., 1998). The mouse GnRHR I
proximal promoter was the first to be isolated and characterized (Albarracin et al., 1994).
The major transcription start site in primary pituitary tissue and αT3-1 cells is located at
−62 (all numbering is relative to the translation start site) and is not associated with a
consensus TATA box (Sadie et al., 2003; Albarracin et al., 1994). In addition to this site,
Clay et al. (1995) identified other pituitary transcription start sites at −90 and −200 bp in
αT3-1 cells. Regulation of the basal activity of the mouse promoter in αT3-1 cells is
conferred by a tripartite basal enhancer, which includes binding sites for steroidogenic
factor-1 (SF-1) at −244/−236, activator protein-1 (AP-1) at −336/−330, and GnRHRactivating sequence (GRAS) at −391/−380 (Duval et al., 1997).

The pan-pituitary

homeobox transcription factor Pitx-1 has been shown to interact with AP-1 in intact
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LβT2 cells, indicating that this interaction might be important for GnRHR I gonadotrophspecific, basal promoter activity (Jeong et al., 2004). In addition, the promoter region
around −360, shown to bind LHX3 homeodomain protein in vitro and in intact cells, was
recently demonstrated to be important for mouse GnRHR I basal promoter activity in
αT3-1 cells (McGillivray et al., 2005).
In the rat proximal GnRHR I promoter, the transcription start site in αT3-1 cells
was initially found to be 103 bp upstream from the start codon, with a putative TATA
box 23 bp upstream from the transcription start site (Reinhart et al., 1997). Later, five
major transcription start sites in αT3-1 cells were identified, including four of them are
clustered around −103, and one is located at −30, along with several minor start sites
(Pincas et al., 1998). Maximal cell specific expression of the rat GnRHR I is achieved by
multiple regulatory domains within 1260 bp of 5′ flanking region. A distal GnRHRspecific enhancer (GnSE), located between −1135 and −753, contains binding sites for
GATA-related and LIM homeodomain-related factors, and facilitates gonadotrophspecific expression through functional interaction with an SF-1 site at − 245 (Pincas et al.,
1998; Pincas et al., 2001). AP-1 site in the rat promoter is also involved in basal
promoter activity, but has no influence on the GnSE function (Hapgood et al., 2005).
The function of the proximal rat promoter and the GnSE is supported by results obtained
in transgenic mice, showing that the proximal 1.1-kb rat GnRHR I promoter is sufficient
to drive gonadotroph-specific expression. Furthermore, 3.3 kb of the rat promoter was
found to drive cell-specific expression of the transgene in gonadotrophs and certain areas
of the brain (Granger et al., 2004).
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The 5′ flanking regions of the human and sheep genes are much more complex
than that of the mouse and rat genes, with the presence of multiple transcription start sites
and CAP sites (Campion et al., 1996; Ngan et al., 2000). Although the sheep proximal 5′
flanking region is structurally similar to the mouse promoter, it has greater sequence
homology to the human promoter (Campion et al., 1996). In contrast to the single start
site identified in mouse pituitary tissue (Sadie et al, 2003), 18 transcription start sites
have been identified for the human GnRHR I gene in human pituitary tissue (Kakar,
1997). These start sites are located between −1748 and −577 and are well dispersed
among several TATA and CCAAT boxes. The proximal 173 bp of the human 5′ flanking
region is critical for basal promoter activity in αT3-1 cells (Ngan et al., 1999). However,
upon limited availability of human gonadotropic cell lines, the results in mouse cell lines
may not be physiologically relevant (Hapgood et al., 2005). The mouse, rat and human
promoters all contain several SF-1 sites, with at least one site in each promoter occurring
in the 5′ untranslated region (UTR). For the human promoter, this site is located at
−140/−134 and is primarily responsible for mediating high cell-specific expression in
αT3-1 cells (Ngan et al., 1999), whereas for the mouse and rat, it is situated at −15/−7 in
both species and has no function for the cell-specific expression (Sadie et al., 2003). An
upstream Oct-1 binding at −1718 is also required for basal activity of the human
promoter in αT3-1 cells (Cheng et al., 2001).
The transcription factor Oct-1 appears to regulate basal GnRHR I gene expression
both positively and negatively, depending on the species and cell-type (Hapgood et al.,
2005). For example, Oct-1 is required for basal expression of the human GnRHR I gene
in several cell types, including placental, ovarian and gonadotroph cell lines, via an Oct-1
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binding site at −1718 (Cheng et al., 2001). On the other hand, in placental JEG-3 cells,
ovarian OVCAR-3 cells and αT3-1 cells, Oct-1 acts as a potent repressor of the human
GnRHR I promoter via a negative regulatory element (NRE) at position −1017 (Cheng et
al., 2002). Oct-1 is also involved in basal and GnRH-stimulated activity of the mouse
GnRHR I promoter in αT3-1 cells via the SURG-1 (Sequence Underlying
Responsiveness to GnRH) element (Kam et al., 2005).
The mouse CRE has been found to be essential for basal promoter activity in
some pituitary cell lines, such as LβT2 cells (Hapgood et al., 2005) and GGH3
somatolactotroph cells (Maya-Nunez and Conn, 1999), but the rat CRE does not appear
to be involved in basal promoter activity in αT3-1 cells (Pincas et al., 2001). A CRE at
position −1650 is required for placenta-specific expression of the human GnRHR I gene
(Cheng et al., 2001). These findings demonstrate that CREs contribute to a cell- and/or
species-specific expression of GnRHR I gene.

Transcriptional Regulation of GnRHR by GnRH
Homologous regulation of the GnRHR is a physiologically relevant mechanism
for increasing pituitary sensitivity to GnRH during ovulation (White et al., 1999).
Therefore, GnRH activation of GnRHR is a potent stimulus for increased expression of
multiple genes including the gene encoding the GnRHR itself. GnRH regulates the
GnRHR with short-term exposure to hormone leading to an increase in receptor
expression, whereas prolonged exposure leads to receptor down-regulation (Norwitz et
al., 1999).

It is widely accepted that pulsatile GnRH stimulation is essential for

appropriate GnRHR expression levels, at the same time avoiding receptor down-
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regulation due to continuous hormonal stimulation (Liu et al., 2003). The effects of
GnRH on GnRHR protein and/or mRNA levels in primary pituitary cultures and cell
lines suggest a direct mechanism of GnRH on pituitary cells, with a combination of both
transcriptional and post-transcriptional mechanisms regulating GnRHR expression levels
(Hapgood et al., 2005). For example, in attempts to mimic the situation in vivo, rat
pituitary cultures were stimulated with GnRH in a pulsatile fashion, resulting in increased
GnRHR mRNA levels (Kaiser et al., 1993) via MAPK and possibly also cAMP/PKA
pathways (Haisenleder et al., 1998; Borgeat et al., 1972). Different pulse frequencies
were found to have different effects on GnRHR mRNA, with higher pulse frequencies
causing maximal stimulation (Kaiser et al., 1997).
The expression levels of mouse GnRHR promoter–reporter constructs transfected
into αT3-1 cells increase in response to 100 nM GnRH after 4–6 h of continuous
stimulation (Norwitz et al., 1999). This GnRH responsiveness was identified to two
regions, designated SURG-1 and SURG-2 (Norwitz et al., 1999). SURG-1 contains
binding sites for nuclear factor Y (NF-Y) and Oct-1, and it was shown by chromatin
immunoprecipitation assays that GnRH increased binding of these factors to SURG-1 in
intact cells (Kam et al., 2005).

GnRH responsiveness via SURG-2 appears to be

mediated by PKC-induced activation of JNK which increases expression, activity and
binding of AP-1 proteins to SURG-2 (Ellsworth et al., 2003). SURG-1 and SURG-2 can
respond to GnRH independently, but the AP-1 element is critical for conferring maximal
GnRH responsiveness (Norwitz et al., 1999). These findings are consistent with the
results obtained in transgenic mice (Ellsworth et al., 2003). However, in the mouse
promoter, responsiveness to GnRH also involves binding of Smad and AP-1 factors to
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another composite element called GRAS, which occurs further upstream at position
− 391/−380 (Norwitz et al., 2002; Norwitz et al., 2002).
In LβT2 cells, endogenous GnRHR mRNA and protein levels are up-regulated
upon long-term pulsatile GnRH stimulation (Turgeon et al., 1996; Bedecarrats et al.,
2003), whereas long-term continuous stimulation down-regulates receptor levels
(Bedecarrates et al., 2003). However, both continuous and pulsatile stimulation induced
only a small increase in the activity of a transfected 1.2 kb mouse GnRHR promoter
(Bedecarrates et al., 2003). Stanislaus et al. (1994) studied the regulation of mouse
GnRHR promoter activity in the GGH3 cell line, which was engineered by stably
transfecting GH3 rat somatolactotroph cells with rat GnRHR cDNA. They found several
intracellular signaling pathways involved in mediating the up-regulation of the mouse
GnRHR promoter activity by GnRH in these cells, such as PKA (Lin and Conn, 1998),
PKC and the Ca2+ signaling pathway (Lin and Conn, 1999). In contrast to the results in
αT3-1 cells, the AP-1 site does not appear to be involved (White et al., 1999; Norwitz et
al., 1999; Maya-Nunez and Conn, 2003). However, functional studies indicate a role for
the PKA pathway and cAMP response elements (CREs) in regulating GnRHR promoter
activity in mouse, rat and human. These results may indicate differences in GnRHR Gprotein coupling between the cell lines. All of these promoters contain functional CREs
and are up-regulated by activators of the PKA pathway in αT3-1 cells (Sadie et al., 2003;
Pincas et al., 2001; Cheng and Leung, 2001). Other factors likely to be involved in
mediating PKA responses are CREB (Tsutsumi et al., 1995) for the rat and SF-1 (Sadie et
al., 2003; Pincas et al., 2001) for the rat and mouse promoters.
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Transcriptional Regulation of GnRHR by Steroid Hormones
Estradiol. Studies in rat, sheep and cow conclude that estradiol increases the
level of GnRHR mRNA and protein in pituitary consistent with a requirement for a
strong, prolonged LH surge for ovulation during the preovulatory phase of the
reproductive cycle (Crowder and Nett, 1984; Savoy-Moore et al., 1980). Experiments in
ovariectomized transgenic mice harboring a sheep GnRHR promoter-reporter construct,
as well as experiments in sheep primary pituitary cells, suggest that transcription is the
predominant mechanism of estradiol up-regulation of GnRHR numbers in the pituitary
(Duval et al., 2000; Wu et al., 1994; Laws et al., 1990; Gregg et al., 1990). However,
estradiol stimulation of αT3-1 cells was found to down-regulate GnRHR numbers
(McArdle et al., 1992), whereas estradiol stimulation of LβT2 cells had little effect on
endogenous GnRHR gene expression (Turgeon et al., 1996; McArdle et al., 1992). These
conflicting results highlight the apparent discrepancies that may occur when using
transformed cell lines compared to primary cells that contain mixed cell populations. In
addition, Turzillo et al. (1994) reported that the GnRHR I mRNA levels increase before
an increase in circulating concentration of estradiol and this result leads to postulate that a
decrease in progesterone, rather than an increase in estradiol, is required for up-regulation
of GnRHR I numbers.
Progesterone. In most mammals, high levels of progesterone correlate with
reduced GnRHR I protein levels in pituitary and reduced pituitary responsiveness to
GnRH I during the luteal phase of the menstrual cycle and during pregnancy (Crowder
and Nett, 1984; Batra and Miller, 1985; Sakurai et al., 1997). In sheep pituitary cells,
GnRHR numbers were dramatically down-regulated by progesterone within 48 h (Wu et
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al., 1994; Laws et al., 1990), consistent with a direct effect of progesterone on the
pituitary. Progesterone was also able to prevent estradiol- and inhibin-induced increases
in GnRHR I mRNA levels in these cells. Recent results with the human GnRHR I
promoter in αT3-1 cells showed that progesterone administration and overexpression of
progesterone receptor (PR) isoforms inhibited GnRHR I promoter activity (Cheng et al.,
2001), suggesting that, at least for the human promoter, repression by progesterone
occurs via direct transcriptional effects on the GnRHR I promoter in gonadotrophs
(Hapgood et al., 2005). Furthermore, this negative effect was shown to occur via a
glucocorticoid response element (GRE)/progesterone response element (PRE) at
−535/−521, which has 75% homology to a consensus progesterone response element, and
to which PR isoforms were shown to bind in vitro (Cheng et al., 2001). In the same
study, a half-PRE binding site was shown to be located at −402/−397. However, this site
did not show a function in the progesterone-mediated transcriptional effects.
Interestingly, another putative GRE/PRE is located further upstream (Fan et al., 1995),
but its function remains unknown.

Testosterone.

In male rats, pituitary GnRHR I mRNA levels appear to be

repressed by testosterone because a negative correlation exists between mRNA levels and
testosterone concentrations in serum (Kaiser et al., 1993; Zapatero-Caballero et al.,
2003). GnRHR I numbers in primary pituitary cultures from male rats decreased after
treatment with α-dihydrotestosterone (Tibolt and Childs, 1985), consistent with in vivo
results and suggesting direct actions of α-dihydrotestosterone on the pituitary.

In
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contrast, α-dihydrotestosterone up-regulated GnRHR I mRNA levels in LβT2 cells
(Curtin et al., 2001).

Transcriptional Regulation of GnRHR by Growth Factors and Other Regulators
Activin and inhibin, both members of the transforming growth factor-β family of
proteins, are produced by primary gonadotrophs (Roberts et al., 1992), αT3-1
(Fernandez-Vazquez et al., 1996) and LβT2 cells (Pernasetti et al., 2001), and exert
autocrine/paracrine effects on pituitary cells. Activin-A stimulates the rate of synthesis
of new GnRHRs in rat pituitary cell cultures (Braden and Conn, 1992), and decreases
receptor numbers in sheep pituitary cultures (Gregg et al., 1991). Inhibin was found to
prevent the stimulation of receptor synthesis by GnRH I in rat pituitary cultures (Braden
et al., 1990), but increases GnRHR I mRNA levels (Wu et al., 1994) and receptor
numbers (Gregg et al., 1991) in sheep pituitary cultures. In αT3-1 and LβT2 cells, longterm stimulation with activin-A up-regulates endogenous GnRHR I mRNA synthesis and
mouse GnRHR I promoter-reporter activity (Fernandez-Vazquez et al., 1996; Pernasetti
et al., 2001), and pretreatment of αT3-1 cells with activin enhances the response of the
mouse GnRHR I promoter to GnRH I (Norwitz et al., 2002). Follistatin blocks the
activin-mediated stimulation at both mRNA and promoter level. In addition, follistatin
decreases the basal activity of the mouse GnRHR I promoter in αT3-1 and LβT2 cells,
indicating that endogenous activin maintains basal GnRHR I expression levels in these
cells (Norwitz et al., 2002; Fenandez-Vazquez et al., 1996; Penasetti et al., 2001).
Activin responsiveness of the mouse GnRHR I promoter was mapped to the GRAS
element (Duval et al., 1999) described earlier, together with a region immediately
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downstream from GRAS, termed DARE (down-stream activin regulatory element)
(Cherrington et al., 2005). The mouse GRAS element is a composite regulatory element
for which the functional activity in αT3-1 cells depends on the proper organization and
assembly of a multiprotein complex, which includes Smad, AP-1 and FoxL2 proteins
(Ellsworth et al., 2003). Basal GnRHR I promoter activity, as well as responsiveness to
GnRH I and to activin require binding of Smad factors to the Smad binding element, as
well as binding of AP-1 to a novel AP-1 element contained within GRAS (Norwitz et al.,
2002; Norwitz et al., 2002). The LIM-homeodomain protein LHX2 was shown to bind
the DARE sequence in vitro (Cherrington et al., 2005). It has been postulated that activin
responsiveness requires a specific configuration of multiple transcription factors on these
distinct elements, to form a complex activin-responsive ‘enhanceosome’ (Cherrington et
al., 2005). Interestingly, the sequence of the corresponding GRAS element in the rat
Pincas et al., 2001; Cherrington et al., 2005), suggesting that the rat DARE sequence is
nonfunctional for activin responsiveness.
Pituitary adenylate cyclase activating polypeptide (PACAP) is a hypothalamic
peptide hormone that modulates pulsatile GnRH I release from the hypothalamus and
responsiveness to GnRH I, as well as regulates gonadotropin subunit expression
(Rawlings and Hezareh, 1996). The mouse, rat and human GnRHR I promoters have all
been shown to be regulated by PACAP in αT3-1 cells (Sadie et al., 2003; Pincas et al.,
2001; Cheng and Leung, 2001). For the rat and human promoters, this has been shown to
involve PKA (Pincas et al., 2001; Cheng and Leung, 2001). Two promoter elements,
designated PARE (PACAP response element) I and PARE II, are required for the
PACAP response of the rat GnRHR I promoter. PARE I includes the SF-1 binding site at
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position −245/−237, along with binding sites for additional factors, whereas PARE II
contains an imperfect cAMP response element (CRE) at position −110/−103 that can
bind CREB (Pincas et al., 2001).

Both the SF-1 site and the imperfect CRE are

conserved in relative position in the mouse GnRHR I promoter, raising the possibility
that a similar mechanism could be responsible for the PACAP response of the mouse
promoter.

Stress and Reproduction

Glucocorticoids (GC) and Glucocorticoid Receptor (GR)
GCs are steroid hormones that are synthesized and secreted from the adrenal
cortex in response to stress via hypothalamic-pituitary-adrenal (HPA) axis.

HPA

activation leads to the release of the neurohormone corticotrophin-releasing hormone
(CRH). The release of CRH causes an increase in the adrenocorticotrpic releasing
hormone (ACTH) and cortisol levels resulting in the activation of the sympathetic
nervous system causing an increase in glucose levels, heart rate and blood pressure
(Smoak and Cidlowski, 2004). General functions of GC are the regulation of glucose,
fat, and protein metabolism. GC are also important for the protection of the body against
stress by regulating glucose metabolism and blood pressure (De Bosscher et al., 2001).
In addition, they have an important role in the dynamic modulation of the inflammatory
and immune responses.

The action of GC is caused by the interruption of pro-

inflammatory, cytokine-mediated signaling pathways and by causing apoptosis in certain
cells of the immune system.

In several immune and inflammatory diseases, which
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include rheumatoid arthritis, inflammatory bowel disease and asthma, exogenous
synthetic GC are prescribed. The biological actions of GC as anti-inflammatory agents
exert their actions via the interaction of this hormone with its cognate receptor, which is a
member of the nuclear receptor superfamily of proteins (Smoak and Cidlowski, 2004).
GCs act through the glucocorticoid receptor (GR), a member of the superfamily
of nuclear receptors (Griekspoor et al., 2007). In the absence of ligand, GR resides in the
cytosol as part of a chaperone-containing multi-protein complex, which maintains a high
affinity for the ligand. Upon hormone binding, GR translocates to the nucleus, where it
acts as a transcription factor (TF). The GR subunits homodimerize and bind DNA at
glucocorticoid response elements (GREs) in the vicinity of target genes (Schoneveld et
al., 2004).

GRE-bound GR recruits multiple transcriptional co-activator complexes,

which stimulate transcription (Jenkins et al., 2001; Schaaf and Cidlowski, 2002). These
properties of GR are reflected by its modular structure (Fig).

The central domain

contains two zinc fingers providing a dimerization interface as well as the DNA binding
domain (DBD; Beato et al., 1995). The C-terminal ligand-binding domain (LBD) is
responsible for high affinity binding of GCs. The LBD overlaps with the activation
domain AF2 (activation domain 2), which is exposed after a conformational change
induced by ligand binding (Kumar and Thompson, 2003). The exposed AF2 mediates
the interaction with co-activators. The N-terminal part of the receptor contains AF1, a
ligand-independent activation function, required for transcriptional enhancement through
the recruitment of co-activators, and association with basal transcription factors (Kumar
and Thompson, 2003). The trans-activation function of GR cannot solely account for the
numerous physiologic effects of GCs. GR also controls many cellular processes by
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influencing multiple pathways in a trans-activation independent manner. In particular,
GR modulates, positively or negatively, the trans-activation function of other TFs. The
modulation may also function the other way around, GR transcriptional activity being
potentiated or inhibited by another TF. The regulation can be either indirect, resulting
from an interference with upstream signaling pathways regulating the activation of TFs,
or can result from a direct mutual regulation of GR and the other TF at the promoter of
the target gene (Kassel and Herrlich, 2007).

Regulation of Transcription Activity via GR Binding to DNA
Glucocorticoids action is mediated via glucocorticoid receptor (GR), nuclear
receptor that regulates physiological events through activation or repression of target
genes involved in inflammation, gluconeogenesis and adipocyte differentiation. In the
absence of glucocorticoid ligand, GRs exist in the cytoplasm in a multimeric complex
composed of heat shock proteins (HSPs), including hsp90, hsp56 and hsp40, p23, Src,
and others (Dittmar et al., 1997; Hawle et al., 2006).

Ligand binding induces a

conformational change in GR that leads to its dissociation from the multimeric complex,
resulting in its dimerization and then rapid translocation into the nucleus and can elicit
changes in gene expression (Croxtall et al., 2000; Ford et al., 1997 Glass and Rosenfeld,
2000). Translocated ligand-bound GRs, then, induce transcriptional regulation through
several different ways.

Direct activation via DNA Binding. GR can bind DNA directly to regulate
target gene expression through glucocorticoid response element (GRE), which is specific
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DNA sequences, recognizing activated GRs. If the GRE is in close proximity to the
TATA-box, GR can recruit key components of the basal transcriptional machinery to the
TATA-box, such as Transcription Factor IID (Ford et al., 1997), and thus directly
promote gene activation. If the GRE is located at a distance of the TATA element, GR
can associate with coactivators that function as bridges to promote the recruitment of the
basal transcriptional machinery (Rosenfeld and Glass, 2001; Tronche et al., 2004).
Furthermore, GR can also recruit chromatin-remodeling coactivators that alter the
nucleosomal structure of the DNA and create a more favorable environment for gene
expression.

Examples of genes positively regulated by GREs include tyrosine

aminotransferase, alanine aminotransferase, and phosphoenolpyruvate carboxykinase, all
involved in liver gluconeogenesis (Tronche et al., 2004).

Indirect Activation via Protein-Protein Interaction. GR can regulate gene
activity independent of DNA binding via protein-protein interactions with other
transcription factors. Example of this mechanism is GR and Signal Transduction and
Transcription proteins (STATs) interaction (Schindler, 1999; Zhang et al., 1997). STATs
are transcription factors involved in the Janus kinase (JAK) signaling pathway.
Activation of JAK signaling results in the phosphorylation and dimerization of STATs,
leading to their translocation into the nucleus and subsequent interaction with their
response elements in the DNA. In this case, STAT-5 physically interacts with GR.
STAT-5 is directly associated with the DNA, while GR is recruited to the chromatin
without direct interaction with the DNA. The GR-STAT-5 association leads to activation
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of several genes, most notably IGF-1 in the liver that is required for postnatal growth
(Zhang et al., 1997).

nGRE Mechanism. Direct DNA binding by GR can also lead to repression of
genes by interactions with negative GREs (nGREs). nGREs are similar to GREs and
almost always are located in close proximity to DNA-binding sites for other transcription
factors necessary for gene expression. The osteocalcin gene promoter, for instance,
contains an nGRE that overlaps with its TATA box, and GR association with this site
prevents access from the basal transcriptional machinery (Meyer et al., 1997).

For

example, the human FasL gene contains an nGRE adjacent to a nuclear factor κ B
(NFκB) site (Novac et al., 2006). GR-nGRE association in this site prevents NFκB
binding and induces gene silencing (Ghosh and Karin, 2002). Pro-opiomelanocortin
(POMC), Corticotropin-releasing hormone (CRH), prolactin and neuronal serotonin
receptor are down-regulated by this interaction.

Indirect Repression via Protein-Protein Interaction.

most of the genes

repressed by GR occur via protein-protein independent of DNA binding by the receptor.
This signaling mechanism includes NFκB, activator protein-1 (AP-1), and Smad3. NFκB
is a ubiquitous homo/heterodimer transcription factor most widely known for its role in
inflammation. The p50/p65 heterodimer is the most common combination involved in
transcriptional processes (McKay and Cidlowski, 1998). GR can physically bind to p65
and repress the NFκB-mediated transcription. For example, the interaction of GR with
p65 can result in the sequestering of the NFκB complex, thereby preventing NFκB from
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reaching its DNA-binding site (Almawi and Melemedjian, 2002). GR can also interact
with DNA-bound NFκB to inhibit the recruitment of the transcriptional machinery. GR
can also suppress NFκB transactivation by interfering with the cellular machinery
necessary for gene activation (Nissen and Yamamoto, 2000). Classical gene targets of
NFκB that are repressed by GR include many pro-inflammatory cytokines and their
receptors, such as tumor necrosis factor α (TNFα), interleukin-1β, and granulocyte
monocyte colony stimulation factor. Similar to NFκB, GR can bind and repress the
transcriptional activity of AP-1 (Shaulian and Karin, 2002; Schule et al., 1990). AP-1 is
a homo/heterodimer transcription factor composed of Fos family or Jun family members.
GR physically interacts with AP-1 and inhibits AP-1-mediated gene activation by
employing similar mechanisms to the NFκB.

Genes repressed by GR in an AP-1-

dependent manner include collagenase, stromelysin, and other matrix metalloproteinases.
In addition to NFκB and AP-1, GR physically interacts with Smad3 and greatly reduces
the transcriptional activity of Smad3, which is phosphorylated by activated tumor growth
factor β (TGFβ) receptor (Song et al., 1999; Li et al., 2003). TGFβ-Smad signaling is
important for cell differentiation, extracellular matrix production, as well as immune and
inflammatory responses.

The HPA-HPG Link
Many studies have been performed to link the HPA axis to the HPG axis.
Recently, it was found that when rodents and non-human primates were treated with
CRH, an immediate decrease in pulsatile GnRH and LH release (Smoak and Cidlowski,
2004; Xia et al., 1996; Feng et al., 1991). In humans, when the HPA axis is activated by
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stress or by psychological disturbances, it results to an inhibition of the HPG axis. If
stress is severe enough, then it can lead to suppression of the normal menstrual cycle,
which is referred to as functional hypothalamic amenorrhea and can lead to infertility
when fully established (Reifenstein, 1946). The final neuroendocrine events resulted in
the suppression of the normal cycle is a decrease in the GnRH pulse generator resulting
in a decrease in the hypothalamic GnRH activity and GnRHR number, leading to a
decrease in the LH pulse frequency and eventually causing deficiencies in the normal
menstrual cycle (Ferin, 1999). CRH may not be the only HPA neurohormone involved in
the stress response. There is good evidence in the human and in animals that vasopressin
of paraventricular origin is colocalized with CRH in perikarya and secretory granules and
coreleased in stress (Mouri et al., 1993; Battaglia et al., 1997). Vasopressin is known to
act synergistically with CRH as an ACTH secretagogue (Rivier et al., 1984).
Experiments using μ-opiate receptor antagonist indicate that an increased
endogenous opioid activity may somehow also account for the decreased pulsatility of the
GnRH pulse generator in patients with functional hypothalamic chronic anovulation
(Ferin, 1999). For example, studies have shown that the administration of naloxone or
naltrexone acutely restores normal LH pulse frequency, at least in a subgroup of these
patients (Khoury et al., 1987). In animals, the acute inhibitory action of CRH on pulsatile
LH release is also clearly prevented by naloxone or by an antiserum to β-endorphin
(Rivest et al., 1993; Gindoff and Ferin, 1987; Petraglia et al., 1986). These human and
animal studies suggest that increased endogenous opioid activity reflects enhanced
central CRH release and mediates the endocrine actions of CRH on the HPG axis and
support the existence of a HPA-HPG link (Ferin, 1999).
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Although the classical HPA-HPG link implies that activation of HPA will cause a
decline in gonadotropin secretion, recent studies suggest that a reverse outcome is
possible under a defined endocrine condition (Ferin, 1999). For example, activation of
HPA by IL-1 or endotoxin in the monkey during the midlate follicular phase (but not the
early follicular phase or the luteal phase) results in an acute release of LH (Xiao et al.
1996). This observation evidently contrasts with the inhibitory effect of the cytokine on
pulsatile LH secretion in the absence of estradiol (Feng et al., 1991). A release of LH
after HPA activation can also be produced in the ovariectomized monkey replaced with
mid- to late follicular phase estradiol levels (Xiao et al., 1994). This study indicates that
the factor that is probably responsible for this acute stimulatory effect of HPA on LH
release may be progesterone, as this effect is readily prevented by the administration of a
progesterone antagonist (Xiao et al., 1994). Xiao et al. (1994) have speculated that in
stress, the small but significant increase in adrenal progesterone that occurs in response to
HPA activation synergizes with circulating estradiol to enhance LH secretion. This
hypothesis was supported by the observation that the increase in LH is prevented by the
administration of a CRH antagonist, demonstrating that HPA activation is required for
this effect to occur (Xiao et al., 1994).

Transcriptional Regulation of GnRHR by Glucocorticoid
It is well documented that chronic or prolonged stress results in inhibition of
gonadotropin secretion and inhibition of reproduction in mammals, whereas the effects of
acute stress are less clear and can even stimulate reproduction (Tilbrook et al., 2000).
Although the mechanisms whereby stress regulates reproduction in mammals are not well
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defined, there is evidence that glucocorticoids play an important role in modulating
pituitary responsive to GnRH I, as part of a feedback mechanism from adrenal to
pituitary (Tilbrook et al., 2000; Breen and Karsch, 2004). Further evidence for direct
actions of glucocorticoids on pituitary is provided by findings that cortisol inhibits
GnRH-induced LH release from bovine and porcine primary pituitary cells
(Padmanabhan et al., 1983; Li, 1994). One mechanism whereby glucocorticoids may
regulate GnRH responsiveness in pituitary may be via modulating GnRHR levels. Rosen
et al. (1991) showed that glucocorticoids augmented GnRH I-induced increase in GnRHR
I numbers in castrated testosterone-replaced male rats. However, earlier studies in rats
did not show a change in GnRHR I levels after treatment with corticosterone (Tibolt and
Childs, 1985; Suter et al., 1988). In sheep, administration of cortisol led to a decrease in
GnRHR protein, but did not reduce GnRHR I mRNA levels (Daley et al., 1999). These
experiments suggest that varying effects of glucocorticoids on GnRHR I levels may
depend on species, the cellular milieu, and the dose, type and duration of glucocorticoid
administration. However, a direct positive transcriptional effect of glucocorticoids on the
mouse GnRHR I promoter has been established. Glucocorticoids increased endogenous
GnRHR I mRNA levels in LβT2 cells, whereas pretreatment with GnRH I further
augmented this increase (Turgeon et al., 1996). Glucocorticoids can also directly upregulate activity of the mouse GnRHR I promoter in GGH3 cells (Maya-Nunez and Conn,
2003). Although the tested 1.2 kb of 5′ flank of the mouse gene does not contain a
classical GRE, the glucocorticoid-responsive region of the mouse GnRHR I promoter
was mapped to the AP-1 site at −336 in GGH3 cells (Maya-Nunez and Conn, 2003). The
results from this study suggest that liganded glucocorticoid receptor interacts directly or
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indirectly with AP-1 proteins, such as c-Jun, to increase GnRHR I transcription (MayaNunez and Conn, 2003).
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CHAPTER III

MATERIALS AND METHODS

Materials
Dexamethasone and mifepristone (RU486) were from Sigma (St. Louis, MO) and
Org 31710 was a generous gift from N.V. Organon (Oss, Netherlands). The antibody
specific for PARP-1 (catalog no. 614301) was purchased from BioLegend (San Diego,
CA), whereas the GR antibody (catalog no. sc-1004X) and normal rabbit IgG (catalog no.
sc-2027) were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). For
experiments

using

EMSA,

DNA

TTGTGAAAACCAGGCCATCTG-3’

probe

(-290/-270;

and

sense

antisense

sequence

sequence

5’5’-

CAGATGGCCTGGTTTTCACAA-3’) and competitive oligonucleotides containing
consensus binding sites for specific transcription factors were synthesized by Integrated
DNA

Technologies

(IDT,

Coralville,

IA).

Biotinylated

DNA

probe

(5’biotin/TTGTGAAAACCAGGCCATCTG-3’) was also synthesized by IDT for
biotinylated DNA-pull down assays.

Plasmid Preparation
A reporter vector containing 5118 bp of porcine GnRHR promoter (-5118pGL3)
was constructed by PCR amplification of the 5’ flanking region of the GnRHR gene from
genomic DNA preparations of pigs representing a white crossbred line. The PCR product
was subsequently subcloned into pBluescript SK- (Stratagene, La Jolla, CA). Promoter
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inserts were ligated into a reporter vector containing the cDNA encoding luciferase
(pGL3, Promega Corp., Madison, WI) at the SacI/EcoRV location of the multiple cloning
site. Deletion constructs were made by progressively removing 5’ flanking sequence
(approximately 500 bp) via restriction enzyme digests and subsequent intramolecular
ligation of the remaining vector backbone. Construction of the 100-bp deletion reporter
vectors was achieved by amplifying the specified region of the promoter by PCR with a
Taq DNA polymerase containing 3’ to 5’ exonuclease activity (Bioline, Springfield, NJ).
Next, the fragments were subcloned into pBluescript SK- or pCR-Blunt II (Invitrogen,
Carlsbad, CA), and then finally placed into pGL3.

Gel Extraction. Appropriate plasmid fragments were extracted from agarose
gels with the Qiaex II Agarose Gel Extraction Kit (Qiagen, Inc.). Excised gel slices were
weighed and buffer QX1 was added, followed by the addition of QIAEX II reagent. Gel
slices were incubated at 55°C for 10 min and vortexed every 2 min. Samples were
centrifuged using a Biofuge Pico (Kendro Lab Products) at 16,000 x g for 1 min and
resulting pellets were washed with 500 μl of buffer QX1, followed by 2 washes (500 μl
each) with buffer PE. The pellet was allowed to air dry before it was resuspended in 20
μl of tris-chloride (Tris-Cl; pH 8.5) and incubated at 55°C for 5 min. Samples were then
centrifuged at 16,000 x g for 1 min and the supernatant was collected. Another 20 μl TrisCl (pH 8.5) was added to the pellet, with the incubation and centrifugation process
repeated.

Plasmid fragments were then quantitated using A260 and A280 values

determined with a Pharmacia GeneQuant spectrophotometer (Pfizer, New York, NY) and
allowed to ligate at 15°C overnight.
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Transformation.

For replication purposes, plasmids were transformed into

RbCl competent DH5α cells (Invitrogen Life Technologies Corp.). The plasmid ligation
reaction (5 μl) was added to 50 μl of DH5α cells, gently mixed, and incubated on ice for
30 minutes. Cells were then heated to 42°C for 30 seconds, followed by a two minute
The addition of 200 μl of SOB media (2% tryptone, 0.5% yeast

incubation on ice.

extract, 8.55 mM sodium chloride, 250 mM potassium chloride, 2 M magnesium
chloride) preceded a one hour incubation shaking at 37°C. Depending on the plasmid,
100-200 μl of cells were plated on petri dishes containing LB media (Sigma Chemical
Co., St. Louis, MO) with the addition of ampicillin and incubated inverted overnight at
37°C.

DNA Extraction
Alkaline Lysis Mini Plasmid Preparation. Plasmid DNA was isolated from
RbCl competent DH5α cells (Invitrogen Life Technologies Corp.) for plasmid
screening purposes.

Two ml of LB media (Sigma Chemical Co.) and 2 μl of

ampicillin were inoculated with a single colony of DH5α cells containing an ampicillin
resistant plasmid and allowed to grow, shaking overnight at 37°C. Cells were pelleted
via centrifugation at 16,000 x g for one minute with a Biofuge Pico microcentrifuge
(Kendro Lab Products). Following removal of the supernatant, cell pellets were
resuspended

in

100

μl

ethylenediaminetetraacetic

of
acid

temperature for five minutes.

GTE

(100

[EDTA],

mM
1

M

tris)

glycine,

500

mM

and incubated at room

Sodium hydroxide/sodium dodecyl sulfate (200 μl;

NaOH/SDS solution) was added to each sample. Next, the sample was mixed gently
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and allowed to incubate on ice for five minutes. Samples were incubated another five
minutes following the addition of 150 μl of potassium acetate (5M) and vortexed for
two seconds. Following centrifugation at 16,000 x g, the supernatant was placed in a
clean 1.5-ml microcentrifuge tube, 800 μl of 100% ethanol was added, and tubes were
incubated for two minutes at room temperature. Samples were centrifuged at 16,000 x
g for five minutes, the ethanol was removed, and the pellet was washed with 100 μl
of 70% ethanol. Following another five minutes of centrifugation at 16,000 x g, the
pellet was allowed to dry at room temperature and resuspended in 1X trisethylenediaminetetraacetic acid (TE, pH 8.0).

RNase A (0.5 μl) was added and each

sample was incubated at 37°C or 30 minutes.

All newly constructed plasmids were

screened via endonuclease restriction digestion prior to use.

Plasmid Purification. Following alkaline lysis mini preparation and appropriate
screening with restriction enzymes, 100 ml of LB (with 150 μl ampicillin) was inoculated
with remaining broth culture from the alkaline lysis preparation and grown, shaking
overnight at 37°C. Cells were isolated from the resulting broth culture by 4°C
centrifugation at 6,000 x g for 15 minutes using a Sorvall RC2-B centrifuge (Du Pont Co.,
Newton, CT). Preparation of plasmids for transfection was performed through using the
Plasmid Purification Midi Kit (Qiagen Inc.). Cell pellets were resuspended in 4 ml of
buffer P1 and incubated for five minutes at room temperature, after the addition of 4 ml
of lysis buffer P2. Following incubation, 4 ml of precipitation buffer P3 was added to
each of the samples, and they were incubated on ice for 15 minutes. Samples were
subjected to 4°C centrifugation at 20,000 x g for 30 minutes using a Sorvall RC2-B
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centrifuge (Du Pont Co.) prior to being applied to a resin column. All columns were
equilibrated with buffer QBT before application of the cell lysate.

Columns were

washed twice with 10 ml of buffer QC and plasmid DNA was eluted from the column
with the addition of 5 ml of buffer QF. Plasmid DNA was precipitated by adding 3.5 ml
of isopropanol, followed by centrifugation at 4°C, spinning at 15,000 x g for 30 minutes
using a Sorvall RC2-B centrifuge. Pellets were washed with 2 ml of 70% ethanol and
centrifuged at 4°C for 10 minutes at 15,000 x g in a Sorvall RC2-B centrifuge (Du Pont
Co.). After pellets had been allowed to air dry, they were resuspended in 250 μl of
Millipore water. All purified plasmids were quantitated through the use of a Lambda
EZ 150 spectrophotometer (Perkin Elmer, Boston, MA) and screened with restriction
endonucleases prior to their use in transient transfection assays.

Cell Culture
αT3-1 (Dr. Pam Mellon, Salk Institute, La Jolla, CA) cells were maintained at 37
C in a humidified 5% CO2 in air atmosphere. The αT3-1 cells were cultured in highglucose DMEM (Mediatech, Herndon, VA) supplemented with 5% fetal bovine serum
(FBS), 5% horse serum, 2 mM glutamine, 100 U/ml penicillin, and 100 µg/ml
streptomycin sulfate (Gibco, Grand Island, NY).

Cultures of αT3-1 cells were

maintained on 150-mm cell culture plates (Corning Inc., Corning, NY) in 20 ml of media.

Transient Transfections
Day 1.
protocol.

Transient transfections were performed using a liposome-mediated

On Day 1, αT3-1 cells, typically at 70% confluency, were trypsinized and
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plated for transfection. The cells were washed with 10 ml of 1X phosphate-buffered
saline (PBS) twice following aspiration of media. Cells were trypsinized by adding 3 ml
of 1X trypsin-EDTA (Mediatech Inc., Herdon, VA), incubating at 37°C in a 5% CO2 in
air environment for five minutes. Following incubation, cells were rinsed with 7 ml of
αT3-1 media, with all cell suspensions collected. A sample of cells (100 μl) was diluted
in 900 μl of 1X PBS and 10 μl of this dilution loaded on a hemacytometer for cell counts.
Approximately two million cells were plated onto 6-well cell culture dishes (Corning
Inc.) in 2 ml of αT3-1 culture media.

Day 2. The plasmid used as a control for transfection efficiency was composed of
the Rous Sarcoma Virus promoter fused to the cDNA encoding β-galactosidase (RSVβgal, Stratagene, La Jolla, CA). For each test vector, 291 μl of serum-free DMEM and 9
μl of Fugene6 reagent (Roche Diagnostics Corp., Indianapolis, IN) were aliquoted into
1.5-ml microcentrifuge tubes. As each test vector was transfected in triplicate, sufficient
quantities to result in 900 ng/well of test vector and 100 ng/well of RSV-βGal control
vector were added to the microcentrifuge tube. The mixture was then incubated for a
minimum of 15 minutes prior to adding 96 μl of the mixture (DMEM, Fugene6 and
vectors) to each well.

Day 3. Transfected αT3-1 cells were harvested 20-24 hours after transfection.
Media was aspirated from all wells, followed by two rinses with 1X PBS. Lysis buffer
(200 μl; Galacto-Light kit; Applied Biosystems, Bedford, MA) containing 1 M
dithiothreitol (DTT) was added to each well and the plates were incubated, shaking at
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4°C for 10 minutes. Cell lysates and buffer were collected and centrifuged at 4°C for two
minutes at 16,000 x g using a Spectrofuge 16M microcentrifuge (EandK Scientific,
Campbell, CA). Lysates (20 μl) were transferred to a white 96-well Microflux2 plate
(Thermo Labsystems, Franklin, MA). This was performed in duplicate for respective
luciferase and β-galactosidase assays.

Plates were analyzed for luciferase and β-

galactosidase activity using the Wallac Victor2 instrument (Perkin Elmer). Transfections
were performed a minimum of three times, using three different plasmid preparations.

Protein Extraction
Cytoplasmic and nuclear protein extracts were obtained from αT3-1 cells for their
use in electrophoretic mobility shift assays (EMSAs) using the NE-PER® Nuclear and
Cytoplasmic Extraction Reagents Kit (Pierce Biotechnology, Rockford, IL). Four plates
of αT3-1 cells at 70% confluency each were rinsed twice with 10 ml of 1X PBS before
removing the cells via vigorous washing with buffer containing 10 mM Tris-Cl, 140 mM
sodium chloride (NaCl), and 1 mM EDTA. Cells were then removed from the wash
buffer by centrifugation at 4°C for five minutes using a Beckman TJ-6 centrifuge at 500 x
g (Beckman, Palo Alto, CA). The resultant cell pellet was resuspended in CER I reagent
through vortexing for 15 seconds and incubated on ice for 10 minutes. Protease inhibitor
cocktail (100X stock containing 104 mM AEBSF, 80 μM aprotinin, 2 mM leupeptin, 4
mM bestatin, 150 μM pepstatin A and 140 μM E-64; Sigma Chemical Co.) and
Phosphatase Inhibitor Cocktail Set II (100X stock containing 200 mM imidazole, 100
mM sodium fluoride, 115 mM sodium

molybdate, 100 mM sodium orthovanadate

and 400 mM sodium tartrate dehydrate; CalBiochem, La Jolla, CA) were added
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simultaneously with CER I reagent. CER II reagent was added to the cells, which were
then vortexed and allowed to incubate on ice for one minute. Following incubation, lysed
cells were centrifuged at 4°C for five minutes

using

a

Spectrafuge

16M

microcentrifuge at 16,000 x g (EandK Scientific, Campbell, CA), with resulting
supernatant transferred to a clean 1.5-ml microcentrifuge tube and stored at -80°C. The
remaining pellet was resuspended in NER reagent with the addition of protease and
phosphatase inhibitor cocktails and incubated on ice for 40 minutes with vortexing for 15
seconds every 10 minutes.

Finally, lysed nuclei were centrifuged at 4°C for 10

minutes using a Spectrafuge 16M microcentrifuge (EandK Scientific) at 16,000 x g
before being transferred to a clean 1.5-ml microcentrifuge tube.

Total protein

concentration of nuclear extracts was quantitated using a BCA assay kit and the
accompanying protocol (Pierce Biotechnology).

Nuclear extracts were stored at -80°C

in 100 μl aliquots.

Electrophoretic Mobility Shift Assays (EMSAs)
All oligonucleotides used in EMSAs were annealed prior to use by adding
complementary oligonucleotides (50 μM each) to 1X NET buffer (1 M NaCl, 10 mM
EDTA, 100 mM Tris-Cl, pH 7.5) and Millipore water. Oligonucleotides were first
denatured by heating to 95°C for 10 minutes and then annealed by incubating at 37°C for
30 minutes followed by a 30 minute incubation at 25°C.
Oligonucleotides were end-labeled with [γ-32P]ATP using polynucleotide kinase
(PNK; Fermentas Inc., Hanover, MD) and a forward reaction protocol.

Annealed

oligonucleotide (1 μl) was incubated with 1 μl 10X PNK Buffer A, 4 μl water, 1 μl T4
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PNK and 3 μl [γ-32P]ATP for 30 minutes at 37°C. Following incubation, 35 μl of water
was added to all reactions.

Reaction mixtures were then applied to equilibrated

MicroSpin™ G-25 columns (Amersham Biosciences Corp., Piscataway, NJ) and
centrifuged at 3,000 x g for two minutes using a Mikroliter microcentrifuge (Hettich AG,
Bäch, Switzerland). Following the addition of 10X NET buffer (5μl) to each reaction, 1
μl from each reaction mixture was added to 4 ml of scintillation fluid and counted on a
1900TR liquid scintillation counter (Packard Instrument Co., Meriden, CT).
Electrophoretic mobility shift assays were performed by adding 2X Dignam D
buffer (20 mM HEPES, 20% glycerol, 0.1 M potassium chloride, 0.2 mM EDTA, 0.5
mM DTT), 20 mM DTT, and 2 μg poly(dI•dC) (Amersham Biosciences) to 5 μg of αT31 nuclear extracts. Probe labeled with [γ-32P]ATP (approximately 100,000 cpm) was
added, and the reaction was incubated at room temperature for 20 minutes. In those
assays that included competitor oligonucleotides, the unlabeled, annealed competitor
oligonucleotide was added just prior to the addition of radiolabeled probe. For supershift
assays, a rabbit polyclonal antibody directed against the p65 subunit of NF-κB
(Calbiochem) or an equal amount of rabbit IgG (Santa Cruz Biotechnology, Santa Cruz,
CA)

was

incubated

with

nuclear

extracts

and

binding

components

for

approximately two hours at 4°C, prior to the addition of probe. Polyacrylamide gels were
subjected to electrophoresis in 1X TGE buffer (25 mM tris base, 190 mM glycine, 1 mM
EDTA) for approximately one hour at 100V prior to the addition of binding reactions,
with subsequent separation of bound from free probe by electrophoresis at 30 mA for
approximately 1.5 hours. Gels were then transferred to blotting paper (3 mm; Whatman,
Maidstone, England), dried and exposed to Biomax MS film (Eastman Kodak Co.,
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Rochester, NY) for 20-24 hours at -80°C before being developed using an SRX-101A
medical film developer (Konica Corp., Wayne, NJ).

Western Blot
Nuclear proteins from αT3-1 cells were extracted using the NE-PER® Nuclear and
Cytoplasmic

Extraction

Reagent

Kit

per

manufacturer’s

instructions

(Pierce

Biotechnology, Rockford, IL), quantitated with a BCA Protein Assay (Pierce) and stored
at -80 C. Protein samples (40 μg) were boiled for 5 min in a 2X reducing loading buffer
(130 mM Tris pH 6.8, 4% SDS, 0.02% Orange G, 20% glycerol, 100 mM DTT), cooled
to room temperature and loaded onto an SDS polyacrylamide gel (PAGE) with a 5%
stacking and 10% resolving gel. Gels were run at 40 mA for approximately 90 min and
electrophoresed proteins were transferred to polyvinylidene difluoride (PVDF,
Immobilon –FL, Millipore, Billerica, MA) membrane with a semi-dry electroblotter
(Panther, Owl Separation Systems, Portsmouth, NH). Briefly, PVDF membrane was prewetted in 100% methanol and soaked with the gel in transfer buffer (25 mM Tris pH 8.3,
192 mM glycine, 0.1% SDS, 20% methanol) for 15 min. The proteins were transferred at
200 mA for 1 h. Membranes were blocked with StartingBlock™ (TBS) Buffer (Pierce)
for 30 min at room temperature with agitation. Incubation of primary antibody directed
against the GR (Santa Cruz Biotechnology) was performed in StartingBlock™ (TBS)
Buffer (Pierce) supplemented with 0.05% Tween-20. Antibody was used at 1:1000
dilutions. Blots were incubated with primary antibody overnight at 4 C with gentle
shaking. After incubation the blots were washed four times with TBS-T (20 mM Tris pH
7.6, 137 mM sodium chloride, 0.1% Tween-20). Each wash was performed for 5 min
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with gentle agitation. The secondary antibody, Alexa Fluor 680 goat anti-rabbit IgG
(A21076, Invitrogen, Carlsbad, CA) was diluted 1:8000 in StartingBlock™ (TBS) Buffer
(Pierce) supplemented with 0.01% SDS and 0.05% Tween-20. The incubation was
performed at room temperature for 1 h with gentle shaking. Blots were washed four
times in TBS-T for 5 min with gentle agitation. After a final rinse with TBS, blots were
scanned on the 700 channel of the Odyssey Infrared Imaging System (LI-COR, Lincoln,
NE) following manufacturer’s instructions.

Biotinylated DNA and Protein Pull-down Assay
We performed pull down assay according to a procedure described by Deng et al.
(2003) with minor modifications (Figure 3.1). In brief, 5 ug of 5’-biotinylated DNA
promoter probe containing GRE was mixed with 500 ug of nuclear extract from αT3-1
cells treated with vehicle or 100 nM dexamethasone and 100 ul of 4 % streptavidinagarose beads in Pierce Biotinylated Protein Interaction Pull-Down Kit (product no.
2115, Thermo Fisher Scientific Inc., Rockford, IL). The final volume was adjusted to
500 ul with nuclear extract buffer from the pull-down kit. The mixture was incubated at
room temperature for 1 h with gentle shaking and centrifuged at 5000 × g in a
microcentrifuge for 30 sec. The supernatant was removed and the pellet was washed four
times with 1 ml of iced PBS. The pulled down mixture, then, was resuspended in 50 ul
of Laemmli sample buffer (Bio-Rad) and boiled for 5 min. 25 ul of the samples was
placed in a 4-20 % gradient polyacrylamine minigel to perform SDS-PAGE.
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Figure 3.1. Diagram of biotinylated DNA/protein pull-down assay, SDS-PAGE, and
Mass Spectrometry. In order to identify which protein binds to the 290/270 bp region
during the dex treatment, I utilized a DNA pull-down assay to isolate the oligonucleotideprotein complex, and then separated proteins comprising the complex using SDS-PAGE.
In the gel, protein band was captured between 95kDa and 130kDa in both treatments.
Spots of interest were then excised from the SDS-PAGE gel and sent to the Nebraska
Center for Mass Spectrometry for protein identification. Mass spectrometry results from
both vehicle and 100 nM dexamethasone treated cells revealed Poly (ADP ribose)
polymerase-1 protein.
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Mass Spectrometry
Spots of interest were excised from the SDS-PAGE gel (Figure 3.1) and sent to
the Nebraska Center for Mass Spectrometry (Lincoln, NE) for protein identification using
tandem mass spectrometry (MS/MS) with a Waters Q-TOF Ultima mass spectrometer
(Micromass/Waters, Milford, MA; Figure 3.1). Briefly, excised bands were digested
using the method of Shevchenko et al. (1997) in which samples were washed with
100 mM ammonium bicarbonate, reduced with 10 mM DTT, alkylated with 55 mM
iodoacetamide, washed twice with 100 mM ammonium biocarbonate, digest in situ with
10 ng μl−1 trypsin, and extracted with two 60 μl aliquots of 1:1 acetonitrile:water (v/v)
containing 1% formic acid. The resulting peptides were separated on a C18 reversed
phase column (75 μm × 15 cm; LC-Pacings, Dionex, Sunnyvale, CA), and eluted using a
water + 0.1% formic acid (A)/95% acetonitrile:5% water + 0.1% formic acid (B) gradient
with a 270 nl/min flow rate. The MS/MS data were processed to produce peak lists for
database searching. Sequences were further searched against Matrix Science Database
20060908 (www.matrixscience.com) for peptide mass fingerprints of mouse (52735
sequences in the database) with the significance threshold set at P < 0.05. Molecular
weight search scoring (MOWSE) used an algorithm described in Pappin et al. (1993) to
determine the “rank” of the peptide compared to all matches in the database. MOWSE
was also used in conjunction with the percent coverage and individual ion scores (not
shown) for each amino acid in the peptide to verify homology or the identity of the
protein.
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Bioinformatics and Statistical Analysis
Analyses of sequence for transcription factor binding sites were performed with
the Patch Public 1.0 program (Biobase, Wolfenbüttel, Germany). Data were analyzed
using the general linear models (GLM) procedure of the Statistical Analysis System
software (version 8.2, SAS Institute Inc, Cary, NC). Means for luciferase activity of test
vectors were compared with control values using Dunnett’s t-test, whereas means for
luciferase activity among test vectors were compared using Tukey’s Studentized Range
test. Transfections were performed in triplicate with at least three replicates containing
different plasmid preparations.
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CHAPTER IV

Role of Poly [ADP-ribose] Polymerase-1 (PARP-1) as a Transcription Factor in
Glucocorticoid Regulation of the Porcine GnRH Receptor (GnRHR) Gene.

ABSTRACT
The binding of GnRH to its receptor results in the synthesis and secretion of the
gonadotropins, as well as stimulation of the gene encoding its own receptor. Thus, the
interaction between GnRH and GnRHR represents a central point for regulation of
reproductive function. Glucocorticoids can alter reproduction by reducing GnRH
responsiveness of gonadotropes within the anterior pituitary gland, potentially via
transcriptional regulation of the GnRHR gene. Investigation of this possible mechanism,
however, revealed that transcription of the murine GnRHR gene is stimulated by
glucocorticoids. To determine the effect of glucocorticoids on porcine GnRHR gene
expression, gonadotrope-derived αT3-1 cells were transiently transfected with a vector
containing 5118 bp of 5’ flanking sequence for the porcine GnRHR gene fused to
luciferase for 12 h and treated with increasing concentrations of the glucocorticoid
agonist, dexamethasone (0, 1, 10, 100 and 1,000 nM) for an additional 12 h prior to
harvest. Maximal induction of luciferase activity was detected at 100 nM of
dexamethasone (2-fold over vehicle; P < 0.05), and this response was blocked by the
glucocorticoid antagonist, mifepristone (100 pM). Deletion from 274 to 323 bp upstream
of the translational start site eliminated glucocorticoid responsiveness, suggesting the
presence of a GRE(s) within this region. Electrophoretic mobility shift assays (EMSA)
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using a 32P-labeled oligonucleotide spanning -290/-270 bp of proximal promoter
revealed increased binding of nuclear extracts from αT3-1 cells treated with 100 nM
dexamethasone compared to vehicle. Sequence analysis of this region indicated putative
binding sites for PR, ER, GR, COUP-TF and GATA, as well as RXR α, β, and γ.
However, competitive oligonucleotides for each of these transcription factors, including
GR, were unable to compete for binding to the radiolabeled -290/-270 bp probe in
EMSAs. Mass spectrometry analysis of isolated proteins from a pull-down using a
biotinylated oligonucleotide (-290/-270 bp) identified PARP-1 as the key binding partner.
To confirm the mass spectrometry result, we performed EMSAs with antibodies specific
for either GR or PARP-1. Both the GR and PARP-1 antibodies generated a supershift of
the specific binding complex. Interestingly, addition of the PARP-1 and GR antibodies
together abolished the supershift. Since the competitive oligonucleotide for GR was
unable to abrogate the DNA/protein complex, whereas inclusion of antibodies confirmed
that GR was a member of the specific binding complex, this suggests that GR must
recruit PARP-1 in order to bind the GRE. Inhibition of p38 and ERK1/2 mitogenactivated protein kinase (MAPK) pathways significantly decreased dexamethasoneinduced promoter activity (P < 0.05), indicating the involvement of these signaling
pathways in glucocorticoid stimulation of the promoter. Thus, our working model for
glucocorticoid responsiveness of the porcine GnRHR gene suggests that, upon binding to
its receptor, glucocorticoid triggers phosophorylation of GR by p38 and ERK1/2 MAPK
pathways, resulting in the recruitment of PARP-1 by phosphorylated, ligand-bound GR to
a GRE located within -290/-270 bp of the porcine GnRHR promoter.
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Introduction
The decapeptide gonadotropin-releasing hormone (GnRH) is a key factor that
mediates the function of the hypothalamic-pituitary-gonadal axis in mammals. Generated
by hypothalamic neurons, GnRH is released in an intermittent manner, traveling to
gonadotropes in the anterior pituitary gland via the hypothalamo-hypophyseal portal
system (Fink, 1988). Gonadotropin-releasing hormone binds to high-affinity receptors on
gonadotrope cells resulting in the biosynthesis and secretion of both follicle stimulating
hormone (FSH) and luteinizing hormone (LH), which stimulate steroid synthesis and
gametogenesis in the gonads (Clayton and Catt, 1981; Clarke et al., 1983; Mason et al.,
1986).

Upon binding to its receptor, GnRH regulates expression of at least 4

gonadotropic genes including those encoding: the common α-glycoprotein subunit, the
specific LHβ- and FSHβ-subunits that combine to produce LH or FSH (Hamernik and
Nett, 1988; Gharib et al., 1990), and the GnRH receptor (GnRHR) itself (Sealfon and
Millar, 1995). Transcriptional regulation of GnRHR is mediated by GnRH via protein
kinase A (PKA) and C (PKC) activation of multiple mitogen-activated protein kinase
(MAPK) pathways including extracellular signal-regulated kinase (ERK), c-Jun Nterminal kinase (JNK), p38 MAPK, and ERK5, also known as big MAPK1 (BMK1;
Sundaresan et al., 1996; Roberson et al., 1999; Noar et al., 2000; Liu et al., 2003; Bonfil
et al., 2004). Thus, the interaction between GnRH and its receptor represents a central
point for regulation of reproductive function in mammals.
Many studies have examined responsiveness of the GnRHR gene to hormones
including GnRH (White et al., 1999; Norwitz et al., 1999; Ellsworth et al., 2001; Liu et
al., 2003), estradiol-17β (Gregg et al., 1990; Laws et al., 1990; Wu et al., 1994; Duval et
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al., 2000), progesterone (Laws et al., 1990; Cheng et al., 2001), testosterone (Kaiser et al.,
1993; Curtin et al., 2001; Zapatero-Caballero et al., 2003) activin (Fernandez-Vazquez et
al., 1996; Pernasetti et al., 2001; Norwitz et al., 2002), and inhibin (Braden et al., 1990;
Gregg et al., 1991; Wu et al., 1994). Several reports indicated that GnRH regulates
GnRHR numbers and mRNA levels in the pituitary gland from the rat (Pieper et al., 1982;
Clayton et al., 1982; Kaiser et al., 1993; Bauer-Dantoin et al., 1995), sheep (Turzillo et al.,
1994), and cow (Vizcarra et al., 1997). In contrast, others reported no change in amounts
of GnRHR mRNA after GnRH treatment in the gonadotrope-derived αT3-1 cell line
(Tsutsumi et al., 1993, 1995; Alarid and Mellon, 1995). Besides regulation of the level of
GnRHR mRNA, GnRH can both up- and down-regulate receptor numbers in the pituitary
(McArdle et al., 1987; Uemura et al., 1992; Bauer-Dantoin et al., 1993; Conn et al., 1995).
Norwitz et al. (1999) determined two elements involved in GnRH responsiveness,
sequence underlying responsiveness to GnRH-1 and 2 (SURG-1 and SURG-2,
respectively) and Kam et al. (2005) reported that nuclear factor Y (NF-Y) and octamer
transcription factor-1 (Oct-1) bind to the SURG-1 element to increase basal and GnRHstimulated expression of the mouse GnRHR gene.

White et al. (1999) isolated an

activation protein-1 (AP-1) element within SURG-2 that conferred GnRH responsiveness
of the GnRHR promoter. Moreover, these investigators identified that GnRH regulation
of the GnRHR gene was mediated via activation of an AP-1 element by PKC (White et
al., 1999) and the JNK pathway (Ellsworth et al., 2003). In addition, the GnRHR
activating sequence (GRAS), important to basal promoter activity, also mediated activin
responsiveness in the mouse GnRHR gene (Duval et al., 1999). The binding of Smad3
and 4 proteins to GRAS (Duval et al., 2000) and AP-1 complexes to an overlapping AP-1
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element regulated activin responsiveness (Ellsworth et al., 2003).

Further studies

demonstrated that binding of the LIM homeodomain proteins, LHX2 and 3, to a
downstream activin regulatory element (DARE) is also necessary for activin
responsiveness (Cherrington et al., 2005; Cherrington et al., 2006).
Glucocorticoids can act at both the hypothalamus and anterior pituitary gland to
regulate gonadotropin secretion (Brann and Mahesh, 1991; Tilbrook et al., 2000). Recent
investigations into stress-related influences on reproductive function implicated
glucocorticoids in the physiological regulation of GnRH and its receptors. For example,
glucocorticoids acted directly at the hypothalamus to suppress GnRH synthesis
(Chandran et al., 1994) and reduced the activity of the GnRH pulse-generating center
(Dubey and Plant, 1985).

Similarly, in the anterior pituitary gland, glucocorticoids

decreased GnRH responsiveness of gonadotrope cells (Kamel and Kubajak, 1987;
Baldwin et al., 1991). In contrast to inhibition of GnRH secretion from the hypothalamus
and reduced responsiveness of gonadotropes to GnRH, glucocorticoids also increased
GnRHR mRNA and protein levels.

In male rats, the glucocorticoid agonist,

dexamethasone, acted directly on gonadotrope cells to modulate a GnRH-induced
increase in GnRHR numbers, as well as gonadotropin gene expression and secretion
(Rosen et al, 1991). In addition, dexamethasone treatment increased endogenous GnRHR
mRNA levels in the gonadotrope-derived LβT2 cell line (Turgeon et al., 1996) and
activity of the murine GnRHR promoter in pituitary adenoma-derived GGH3 (MayaNúñez and Conn, 2003) and LβT2 (McGillivray et al., 2007) cells. Maya-Núñez and
Conn (2003) identified the glucocorticoid response element (GRE) as an AP-1 binding
site located between 255 and 331 bp upstream of the transcriptional start site that bound
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the transcription factor, c-Jun, suggesting that ligand-bound glucocorticoid receptors
interact directly or indirectly with c-Jun to regulate GnRHR transcription. Our laboratory
has isolated the porcine GnRHR gene promoter and identified elements conferring basal
activity in αT3-1 cells. The objectives of this study are to determine glucocorticoid
responsiveness of the porcine GnRHR gene, to isolate the

glucocorticoid response

element(s) located within the porcine GnRHR promoter and to examine the molecular
mechanisms underlying glucocorticoid stimulation of GnRHR gene expression in αT3-1
cells.

Materials and Methods

Materials.

Dexamethasone and mifepristone (RU486) were from Sigma

Chemical Co. (St. Louis, MO) and Org 31710 was a generous gift from N.V. Organon
(Oss, Netherlands). The antibody specific for the PARP-1 (catalog no. 614301) was
purchased from BioLegend (San Diego, CA); and the specific antibody for the GR
(catalog no. sc-1004X) and normal rabbit IgG (catalog no. sc-2027) were obtained from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). For experiments using EMSA, DNA
probe (-290/-270; sense sequence 5’-TTGTGAAAACCAGGCCATCTG-3’ and antisense
sequence 5’-CAGATGGCCTGGTTTTCACAA-3’) and competitive oligonucleotides
containing consensus binding sites for transcription factor were synthesized by Integrated
DNA

Technologies

(IDT,

Coralville,

IA).

Biotinylated

DNA

probe

(5’biotin/TTGTGAAAACCAGGCCATCTG-3’) was also synthesized by IDT for
biotinylated DNA-pull down assays.
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Plasmids. A reporter vector containing 5118 bp of porcine GnRHR promoter (5118pGL3) was constructed by PCR amplification of the 5’ flanking region of the GnRH
receptor gene from genomic DNA preparations of pigs representing a white crossbred
line. The PCR product was subsequently subcloned into pBluescript SK- (Stratagene, La
Jolla, CA). Promoter inserts were ligated into a reporter vector containing the cDNA
encoding luciferase (pGL3; Promega Corp., Madison, WI) at the SacI/EcoRV location of
the multiple cloning site. Deletion constructs were made by progressively removing 5’
flanking sequence (approximately 500 bp) via restriction enzyme digests and subsequent
intramolecular ligation of the remaining vector backbone. Construction of the 100-bp
deletion reporter vectors was achieved by amplifying the specified region of the promoter
by PCR with a Taq DNA polymerase containing 3’ to 5’ exonuclease activity (Bioline,
Springfield, NJ). Next, the fragments were subcloned into pBluescript SK- or pCR-Blunt
II (Invitrogen, Carlsbad, CA), and then finally into pGL3.

Cell Culture and Transfections. αT3-1 (Dr. Pam Mellon, Salk Institute, La
Jolla, CA) cells were maintained at 37 C in a humidified 5% CO2 in air atmosphere. The
αT3-1 cells were cultured in high-glucose DMEM (Mediatech, Herndon, VA)
supplemented with 5% fetal bovine serum (FBS), 5% horse serum, 2 mM glutamine, 100
U/ml penicillin, and 100 µg/ml streptomycin sulfate (Gibco, Grand Island, NY).
Transient transfections were performed using a liposome-mediated protocol (Fugene6;
Roche Diagnostics Corp., Indianapolis, IN) following manufacturer’s instructions. The
day prior transfection, cells were plated in 6-well tissue culture plates at the appropriate
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density (between 2 x 105 and 2 x 106 cells) to result in 40% confluency on the day of
transfection. Cells were transfected with a 3:1 Fugene6 to DNA ratio. A total of 1 µg of
DNA, 0.9 µg of luciferase test vector and 0.1 µg of pSV-β-gal were used per well.
Luciferase (Promega Corp.) and β-gal assays (Applied Biosystems, Bedford, MA) were
performed following manufacturer’s instructions. After 12 h transfection, cells were
treated with dexamethasone or progesterone. If mentioned, antagonists were added into
cells 15 min prior to agonist treatment. At 24 h post transfection, cells were washed
twice with ice-cold PBS and harvested with 200 µl of lysis buffer [100 mM potassium
phosphate (pH 7.8), 0.2% Triton X-100 and 1 mM dithiothreitol (DTT)]. Lysates were
cleared by centrifugation at 16,000 x g for 2 min at 4 C and 20 µl of lysate was used to
perform each of the assays. Luciferase and β-gal values for each sample were determined
using a Wallac VICTOR2 micro plate reader (PerkinElmer Life Sciences, Boston, MA).
To normalize for transfection efficiency, luciferase activity was divided by β-gal values.

Electrophoretic Mobility Shift Assays. Nuclear protein extracts were prepared
from αT3-1 cells utilizing the NE-PER® Nuclear and Cytoplasmic Extraction Reagent Kit
according to manufacturer’s instructions (Pierce Biotechnology, Rockford, IL).
Approximately 2.8 x 108 αT3-1 cells were harvested with TNE buffer [10 mM Tris (pH
8), 140 mM NaCl, 1 mM EDTA], and the extracts were treated with protease (catalog no.
P8340; Sigma Chemical Co.) and phosphatase (catalog no. 524625; Calbiochem, La
Jolla, CA) inhibitor cocktails to prevent enzymatic degradation of proteins. The amount
of protein present in the extracts was determined using a bicinchoninic acid (BCA) assay
(Pierce Biotechnology). Oligonucleotide probes were end-labeled with [γ-32P]ATP using
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T4 polynucleotide kinase (MBI Fermentas Inc., Hanover, MD) and purified using
sephadex G-25 spin columns (Amersham Biosciences Corp., Piscataway, NJ). Nuclear
extracts (5 μg) were incubated with 4 μl of Dignam D buffer (20 mM HEPES, 20%
glycerol, 0.1 M potassium chloride, 0.2 mM EDTA, 0.5 mM DTT), 1 mM DTT, 2 μg
poly(dI•dC) (Amersham Biosciences Corp.) and, where indicated, rabbit antiserum
directed against GR (catalog no. sc-1004X; Santa Cruz Biotechnology) or an equal
amount of rabbit IgG (catalog no. sc-2027; Santa Cruz Biotechnology) at 25 C for 30
min. Following incubation, radiolabeled probe (100,000 cpm) was added and, where
indicated, 50-fold molar excess of either homologous or heterologous unlabeled
competitor. Reactions were incubated for an additional 20 min at 25 C before free probe
was separated from bound probe by electrophoresis for 1.5 h at 30 mA in 5 %
polyacrylamide gels that were prerun for 1 h at 100 V in 1 X TGE [25 mM Tris (pH 8.3),
190 mM glycine and 1 mM EDTA]. Gels were transferred to blotting paper, dried, and
exposed to Biomax MS film (Eastman Kodak Co., Rochester, NY) for 20-24 h at -80 C
before being developed.

Western Blot. Nuclear proteins from αT3-1 cells were extracted using the NEPER® Nuclear and Cytoplasmic Extraction Reagent Kit per manufacturer’s instructions
(Pierce Biotechnology), quantitated with a BCA Protein Assay (Pierce Biotechnology)
and stored at -80 C. Protein samples (40 μg) were boiled for 5 min in a 2X reducing
loading buffer (130 mM Tris pH 6.8, 4% SDS, 0.02% Orange G, 20% glycerol, 100 mM
DTT), cooled to room temperature and loaded onto an SDS polyacrylamide gel (PAGE)
with a 5% stacking and 10% resolving gel. Gels were run at 40 mA for approximately 90
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min and electrophoresed proteins were transferred to polyvinylidene difluoride (PVDF;
Immobilon –FL; Millipore, Billerica, MA) membrane with a semi-dry electroblotter
(Panther; Owl Separation Systems, Portsmouth, NH). Briefly, PVDF membrane was prewetted in 100% methanol and soaked with the gel in transfer buffer (25 mM Tris pH 8.3,
192 mM glycine, 0.1% SDS, 20% methanol) for 15 min. The proteins were transferred at
200 mA for 1 h. Membranes were blocked with StartingBlock™ (TBS) Buffer (Pierce
Biotechnology) for 30 min at room temperature with agitation. Incubation of primary
antibody directed against the GR (Santa Cruz Biotechnology) was performed in
StartingBlock™ (TBS) Buffer (Pierce Biotechnology) supplemented with 0.05% Tween20. Antibody was used at 1:1000 dilutions. Blots were incubated with primary antibody
overnight at 4 C with gentle shaking. After incubation the blots were washed four times
with TBS-T (20 mM Tris pH 7.6, 137 mM sodium chloride, 0.1% Tween-20). Each
wash was performed for 5 min with gentle agitation. The secondary antibody, Alexa
Fluor 680 goat anti-rabbit IgG (catalog no. A21076, Invitrogen) was diluted 1:8000 in
StartingBlock™ (TBS) Buffer (Pierce Biotechnology) supplemented with 0.01% SDS
and 0.05% Tween-20. The incubation was performed at room temperature for 1 h with
gentle shaking. Blots were washed four times in TBS-T for 5 min with gentle agitation.
After a final rinse with TBS, blots were scanned on the 700 channel of the Odyssey
Infrared Imaging System (LI-COR, Lincoln, NE) following manufacturer’s instructions.

Biotinylated DNA and Protein Pull-down Assay. We performed pull down
assays according to a procedure described by Deng et al. (2003) with minor
modifications. In brief, 5 ug of 5’-biotinylated DNA promoter probe containing GRE
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was mixed with 500 ug of nuclear extract from αT3-1 cells treated with vehicle or 100
nM dexamethasone and 100 ul of 4 % streptavidin-agarose beads in Pierce Biotinylated
Protein Interaction Pull-Down Kit (product no. 2115; Pierce Biotechnology). The final
volume was adjusted to 500 ul with nuclear extract buffer from the pull-down kit. The
mixture was incubated at room temperature for 1 h with gentle shaking and centrifuged at
5000 × g in a microcentrifuge for 30 sec. The supernatant was removed and the pellet
was washed four times with 1 ml of iced PBS. The pulled down mixture, then, was
resuspended in 50 ul of Laemmli sample buffer (Bio-Rad) and boiled for 5 min. 25 ul of
the samples was placed in a 4-20 % gradient polyacrylamine minigel to perform SDSPAGE.

Mass Spectrometry. Spots of interest were excised from the SDS-PAGE gel and
sent to the UNL Center for Mass Spectrometry (Lincoln, NE) for protein identification
using tandem mass spectrometry (MS/MS) with a Waters Q-TOF Ultima mass
spectrometer (Micromass/Waters, Milford, MA). Briefly, excised bands were digested
using the method of Shevchenko et al. (1997) in which samples were washed with
100 mM ammonium bicarbonate, reduced with 10 mM DTT, alkylated with 55 mM
iodoacetamide, washed twice with 100 mM ammonium biocarbonate, digest in situ with
10 ng μl−1 trypsin, and extracted with two 60 μl aliquots of 1:1 acetonitrile:water (v/v)
containing 1% formic acid. The resulting peptides were separated on a C18 reversed
phase column (75 μm × 15 cm; LC-Pacings, Dionex, Sunnyvale, CA), and eluted using a
water + 0.1% formic acid (A)/95% acetonitrile:5% water + 0.1% formic acid (B) gradient
with a 270 nl/min flow rate. The MS/MS data were processed to produce peak lists for
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database searching. Sequences were further searched against Matrix Science Database
20060908 (www.matrixscience.com) for peptide mass fingerprints of mouse (52735
sequences in the database) with the significance threshold set at P < 0.05. Molecular
weight search scoring (MOWSE) used an algorithm described by Pappin et al. (1993) to
determine the “rank” of the peptide compared to all matches in the database. MOWSE
was also used in conjunction with the percent coverage and individual ion scores (not
shown) for each amino acid in the peptide to verify homology or the identity of the
protein.

Bioinformatics and Statistical Analysis. Analyses of sequence for transcription
factor binding sites were performed with the Patch Public 1.0 program (Biobase,
Wolfenbüttel, Germany). Data were analyzed using the general linear models (GLM)
procedure of the Statistical Analysis System software (version 8.2, SAS Institute Inc,
Cary, NC). Means for luciferase activity of test vectors were compared with control
values using Dunnett’s t-test, whereas means for luciferase activity among test vectors
were compared using Tukey’s Studentized Range test. Transfections were performed in
triplicate with at least three replicates containing different plasmid preparations.

Results
Activity of the porcine GnRHR promoter is regulated by dexamethasone in
dose-dependent manner. To investigate glucocorticoid responsiveness of the porcine
GnRHR gene, we performed transient transfections in αT3-1 cells with luciferase reporter
plasmids containing the full-length porcine GnRHR promoter (-5118pGL3) followed by
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treatment with increasing concentrations of the glucocorticoid agonist, dexamethasone, or
100 nM dexamethasone in combination with increasing amounts of glucocorticoid
antagonist, mifepristone (RU 486; Figure 4.1). Treatment with increasing amounts of
dexamethasone resulted in a dose-dependent increase in promoter activity (P < 0.05) and
optimal promoter activity occurred after treatment with 100 nM of dexamethasone (2fold).

To confirm specificity of this response, we treated cells with 100 nM

dexamethasone and increasing amounts of RU 486 (Figure 4.1). Dexamethasone-induced
promoter activity was reduced to basal levels following treatment with 100 pM RU 486,
suggesting that GR or PR may mediate glucocorticoid responsiveness of the porcine
GnRHR gene (Figure 4.1). Although 10 pM is within the range of GR-specific inhibition
for RU 486, this inhibitor can also interact with PR a dfferent binding affinities.

Dexamethasone responsiveness of the porcine GnRHR gene is mediated by
GR and GR translocation to nucleus.

To investigate whether dexamethasone

responsiveness of the porcine GnRHR gene was mediated by GR or PR, we transiently
transfected αT3-1 cells with luciferase reporter plasmids containing the full-length
porcine GnRHR gene promoter (-5118pGL3) and treated with increasing concentrations
of dexamethasone or 100 nM dexamethasone in combination with increasing amounts of
the progesterone antagonist, Organon 31710 (Org31710; Figure 4.2).

It has been

reported that Org31710 has a similar relative binding affinity for cytoplasmic PR as RU
486, but a much lower binding affinity (over 30-fold) for GR than RU 486 (Kloosterboer
et al., 1994). Similar to results shown in Figure 4.1, dexamethasone-induced luciferase
activity of the GnRHR gene increased in a dose-dependent manner. However, increasing
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Figure 4.1. Luciferase activity of αT3-1 cells transiently transfected with porcine
GnRHR promoter constructs following treatment with increasing concentrations of the
glucocorticoid agonist, dexamethasone, or 100 nM dexamethasone in combination with
increasing amounts of the glucocorticoid antagonist, RU486. αT3-1 cells were transfected
with luciferase reporter (LUC) vectors containing the full length porcine GnRHR
promoter. After 12 h, cells were treated with 0.001, 0.01, 0.1, and 1 uM dexamethasone
or combinations of 0.1 uM dexamethasone and 0.0001, 0.001, 0.01, 0.1, or 1 nM RU486.
RU486 was added to cells 15 min prior to dexamethasone treatment. Cells were cotransfected with RSV-β-gal and, after 24 h of transfection, cells were harvested and
cellular lysates were assayed for LUC and β-gal activity. To control for transfection
efficiency, LUC activity was divided by β-gal values and results are expressed as fold
expression over pGL3. Optimal promoter activity occurred after treatment with 0.1 uM
dexamethasone and activity was reduced to basal levels by 0.1 nM RU486.
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Figure 4.2. Luciferase activity of αT3-1 cells transiently transfected with porcine
GnRHR promoter constructs following treatment with increasing concentrations of the
glucocorticoid agonist, dexamethasone, or 100 nM dexamethasone in combination with
increasing amounts of the progesterone antagonist, Org31710. αT3-1 cells were
transfected with the full length porcine GnRHR promoter. After 12 h, cells were treated
with 0.001, 0.01, 0.1, or 1 uM dexamethasone or combinations of 0.1 uM dexamethasone
and 0.0001, 0.001, 0.01, 0.1, or 1 nM Org31710. Org31710 was added to cells 15 min
prior to dexamethasone treatment. Optimal promoter activity occurred after treatment
with 0.1 uM dexamethasone and activity was reduced to basal levels by 1 nM RU486.
Bars with asterisks are different from controls (P < 0.05).
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amounts of Org31710, at concentrations similar to RU 486, were unable to reduce
dexamethasone-stimulated luciferase activity (Figure 4.2). Therefore, this result indicates
that dexamethasone regulates the porcine GnRHR gene through binding to GR.
Interestingly, 1 nM Org31710 treatment eliminated dexamethasone-induced promoter
activity. However, this is due to the fact that Org 31710 has an affinity for both GR and
PR (Kloosterboer et al., 1994).
Typically, GRs are located within the cytoplasm of the cell in unstimulated
conditions (Dittmar et al., 1997; Hawle et al., 2006). In the presence of ligands, however,
GRs are dimerized and translocated to the nucleus (Croxtall et al., 2000; Ford et al., 1997
Glass and Rosenfeld, 2000). To examine the translocation of GR in αT3-1 cells, we
treated αT3-1 cells with vehicle and 100 nM dexamethasone and analyzed proteins from
these cells using Western blot analysis (Figure 4.3). Nuclear extracts from αT3-1 cells
treated with 100 nM dexamethasone expressed more GR protein in the nucleus compared
to those treated with vehicle. This indicates GR translocation during dexamethasone
exposure.

Sequential 5’ deletions of the full-length porcine reporter construct
demonstrates that the 290/270 bp region of porcine GnRHR promoter is critical for
dexamethasone responsiveness.

To determine the location of the glucocorticoid

response element (GRE), we investigated dexamethasone responsiveness of αT3-1 cells
transiently transfected with reporter vectors containing sequential deletion of 5’ flanking
sequences for the porcine GnRHR gene (Figure 4.4). Reduction of proximal promoter
from 5000 to 320 bp had no effect on dexamethasone-stimulated luciferase activity (P >
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Figure 4.3. Determination of the translocation of GR following treatment with vehicle or
100 nM dexamethasone using western blot analysis. Detailed protocols are described in
Materials and Methods. Briefly, nuclear extracts (40 μg) were boiled for 5 min in a 2X
reducing loading buffer, cooled to room temperature and loaded onto an SDS
polyacrylamide gel (PAGE) with a 5% stacking and 10% resolving gel. Gels were run at
40 mA for approximately 90 min and electrophoresed proteins were transferred to
polyvinylidene difluoride (PVDF, Immobilon –FL, Millipore, Billerica, MA) membrane
with a semi-dry electroblotter (Panther, Owl Separation Systems, Portsmouth, NH).
Incubation of primary antibody directed against the GR (Santa Cruz Biotechnology) was
performed in StartingBlock™ (TBS) Buffer (Pierce) with 0.05% Tween-20 at 1:1000
dilutions. The secondary antibody, Alexa Fluor 680 goat anti-rabbit IgG (A21076,
Invitrogen, Carlsbad, CA) was diluted 1:8000 in StartingBlock™ (TBS) Buffer (Pierce)
supplemented with 0.01% SDS and 0.05% Tween-20. GR concentration was increased
in nucleus while decreased in cytoplasm when αT3-1 cells were treated with 100nM
dexamethasone. This indicates nuclear translocation of the GR in αT3-1 cells during
dexsamethasone stimulation.
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0.05). However, reduction of the promoter from 320 to 270 bp reduced luciferase
activity to basal levels (P < 0.05). Additional deletion vectors within 320 and 270 bp
region were constructed to more precisely locate the GRE (Figure 4.5).

The vector

containing the 320 to 290 bp region of the porcine promoter maintained dexamethasoneinduced luciferase activity, whereas a complete loss in dexamethasone-induced luciferase
activity was observed when the promoter was reduced to 270 bp (P < 0.05). Therefore,
this result suggests that a glucocorticoid response element(s) is located within the -290/270 bp region upstream of the translational start site for the porcine GnRHR promoter.

EMSAs revealed that increased protein binding to the -290/-270 bp promoter
region is responsible for dexamethasone-induced activity of the porcine GnRHR
gene.

EMSAs were performed with αT3-1 nuclear extracts and radiolabeled probe

spanning -290/-270 bp region generated from the porcine GnRHR promoter to identify
binding factor(s) within the -290/-270 region.

Results indicated increased specific

binding complexes to the nuclear extracts from αT3-1 cells treated with 100 nM
dexamethasone compared to vehicle (Figure 4.6). Sequence analysis of this region has
revealed several putative transcription factor binding sites including estrogen receptor
(ER), progesterone receptor (PR), glucocorticoid receptor (GR), signal transducer and
activator of transcription (STAT), sma and mad related protein (SMAD), chicken
ovalbumin upstream promoter transcription factor (COUTP-TF), and retinoid X receptor
(RXR). To determine transcription factor(s) binding to GRE from the sequence analysis
results, EMSAs were performed with αT3-1 nuclear extracts, radiolabeled probe
containing -290/-270 region of the porcine GnRHR promoter, and non-labeled
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oligonucleotides generated from the consensus sequence for each of the putative binding
sites as a competitor. Although ER consensus oligonucleotides competed with the probe
for binding to GRE, we were unable to identify protein(s) comprising the specific binding
complex following addition of antibodies to EMSAs (Figure 4.6). Therefore, I mutated
putative ER binding site, -279/-274 bp and investigated glucocorticoid responsiveness of
the vector whether thie ER site is GRE or not (Figure 4.7). However, the mutation vector
maintained dexamethasone-induced promoter activity, indicating that glucocorticoid
response element is located in different site within -290/-270 bp other than putative ER
binding site.

Binding of GR and poly (ADP-ribose) polymerase-1 (PARP-1) induces
dexamethasone responsiveness of the porcine GnRHR promoter. Since we did not
have any information regarding the binding protein(s), we needed to isolate the protein(s)
from nuclear extracts of αT3-1 cells treated with vehicle or 100 nM dexamethasone. We
performed DNA-protein pull-down assays to separate protein(s) bound to probe
containing the GRE from the nuclear extracts.

Purified samples were sent to the

Nebraska Center for Mass Spectrometry (University of Nebraska-Lincoln, Lincoln,
Nebraska) to identify the protein samples. The mass spectrometry results from both pulldowned samples showed several possible protein identifications (Figure 4.8 and 4.9).
The primarly candidate protein was poly (ADP-ribose) polymerase-1 (PARP-1) in both
vehicle and 100 nM dexamethasone treatment sample with the highest protein score,
1104 and 1478, respectively (Figure 4.8 and 4.9).
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Figure 4.4. Transient transfection of αT3-1 cells with luciferase vectors containing
sequential 5’ deletions of the full-length porcine GnRHR promoter. αT3-1 cells were
transfected with pGL3 constructs containing 5000, 1900, 1400, 1000, 500, 320, 270, 190,
170 and 150 bp of proximal promoter, or promoterless control. After 12 h, cells were
treated with 100 nM dexamethasone for 12 h. Reduction of proximal promoter from 320
to 270 bp inhibited glucocorticoid-stimulated luciferase activity by 50%, indicating the
presence of a glucocorticoid response element(s).
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Figure 4.5. Transient transfection of αT3-1 cells with luciferase vectors containing
sequential 5’ deletions of the full-length porcine GnRHR promoter. Transient
transfections were performed as shown in A with vectors containing 320, 290, 270, and
190 bp of 5’ flanking sequence to more precisely locate the glucocorticoid response
element(s). Results indicate glucocorticoid response element(s) is located between 270
and 290 bp upstream of the translational start site. Bars with different superscripts differ
(P < 0.05).
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B

C

Figure 4.6. EMSA using a radiolabeled probe corresponding to the -290/-270 bp region
of the porcine GnRHR promoter. A, Nuclear extracts (5 µg) from αT3-1 cells treated with
vehicle or 100 nM dexamethasone were incubated with a radiolabeled probe spanning the
-290/-270 region of the porcine GnRHR promoter. To determine the specificity of DNAprotein interactions, we added 50-fold molar excess of unlabeled homologous and
heterologous probe or unlabeled oligonucleotides containing consensus sequences for
specific transcription factor binding sites as competitors. Binding reactions were
subjected to electrophoresis through polyacrylamide gels as described in Materials and
Methods. Increased binding was detected for nuclear extracts from αT3-1 cells treated
with 100 nM dexamethasone compared to those treated with vehicle (70% ethanol). B,
EMSA was performed with PR, ER, and GR consensus oligonucleotides. In addition,
nuclear extracts were incubated with antibodies (1 ug) directed against either ER or
normal rabbit IgG before the addition of radiolabeled probe. However, the ER antibody
did not alter the specific binding complex. C, EMSA was performed with antibodies
directed against GR or poly (ADP-ribose) polymerase (PARP). Arrow indicates supershit
complex. Both PARP and GR antibodies generated a supershift of the specific binding
complex, whereas a combination of PARP and GR antibodies abolished the supershift
generated from the specific binding complex.
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Figure 4.7. Mutation of ER binding site on the porcine GnRHR promoter. The mutation
vector maintained dexamethasone-induced promoter activity, indicating that
glucocorticoid response element is located in different site within -290/-270 bp other
than putative ER binding site.
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A
Database : NCBInr 20100601 (11112683 sequences; 3786819628 residues)
Taxonomy : Mus. (147782 sequences)
Timestamp : 10 Jun 2010 at 21:03:20 GMT
Protein hits: gi|20806109 poly [ADP-ribose] polymerase 1 [Mus musculus]
gi|387397
epidermal keratin subunit I [Mus musculus]
gi|4159806 type II keratin subunit protein [Mus musculus]
gi|12843914 unnamed protein product [Mus musculus]
gi|16303309 type II keratin 5 [Mus musculus]
gi|148672085 mCG144996 [Mus musculus]
gi|13272554 cytokeratin KRT2-6HF [Mus musculus]
gi|22164776 keratin, type II cytoskeletal 79 [Mus musculus]
gi|46485130 TPA: TPA_exp: keratin Kb40 [Mus musculus]
gi|511654
keratin type II [Mus musculus]
gi|398168
keratin 2 epidermis [Mus musculus]
gi|741022
keratin 15
gi|6754480 keratin, type I cytoskeletal 13 [Mus musculus]
gi|6730310 Chain A, Crystal Structure Of The Arf-Gap Domain And Ankyrin Repeats Of Papbeta
gi|74213106 unnamed protein product [Mus musculus]
gi|85701680 keratin, type II cytoskeletal 2 oral [Mus musculus]
gi|7106335 keratin, type I cytoskeletal 17 [Mus musculus]

B
Match to: gi|20806109; Score: 1104; poly [ADP-ribose] polymerase 1 [Mus
musculus]
Nominal mass (Mr): 113506; Calculated pI value: 9.06
Taxonomy: Mus musculus
Sequence Coverage: 41%
Matched peptides shown in Bold
1
51
101
151
201
251
301
351
401
451
501
551
601
651
701
751
801
851
901
951
1001

MAEASERLYR
WYHFSCFWKV
GSGGKAEKTL
LGMIDRWYHP
AIKNEGKRKG
DELKKACSTN
GQLVFKSDAY
VKKQDRIFPP
KLSQNKDEAK
NVRVVCEDFL
AAPSKKSKGA
KVFSATLGLV
LEQMPSKEDA
AVKKLTVKPG
LSRRQIQAAY
LLNNADSVQA
IKVVDRDSEE
FRQLHNRRLL
VSKSANYCHT
LGKTTPDPSA
YLLKLKFNFK

VEYAKSGRAS
GHSIRQPDVE
GDFLAEYAKS
TCFVKKRDEL
DEVDGTDEVA
DLKELLIFNQ
YCTGDVTAWT
ESSAPAPLAL
AVIEKLGGKL
QDVSASTKSL
VKEEGVNKSE
DIVKGTNSYY
VEHFMKLYEE
TKSKLPKPVQ
SILSEVQQAV
KVEMLDNLLD
AEVIRKYVKN
WHGSRTTNFA
SQGDPIGLIL
SITLEGVEVP
TSLW

CKKCSESIPK
VDGFSELRWD
NRSMCKGCLE
GFRPEYSASQ
KKKSKKGKDK
QQVPSGESAI
KCMVKTQNPS
PLSVTSAPTA
TGSANKASLC
QELLSAHSLS
KRMKLTLKGG
KLQLLEDDKE
KTGNAWHSKN
ELVGMIFDVE
SQGSSESQIL
IEVAYSLLRG
THATTHNAYD
GILSQGLRIA
LGEVALGNMY
LGTGIPSGVN

DSLRMAIMVQ
DQQKVKKTAE
KIEKGQMRLS
LKGFSLLSAE
DSSKLEKALK
LDRVADGMAF
RKEWVTPKEF
VNSSAPADKP
ISTKKEVEKM
SWGAEVKAEP
AAVDPDSGLE
SRYWIFRSWG
FTKYPKKFYP
SMKKALVEYE
DLSNRFYTLI
GSDDSSKDPI
LEVIDIFKIE
PPEAPVTGYM
ELKHASHISK
DTCLLYNEYI

SPMFDGKVPH
AGGVAGKGQD
KKMVDPEKPQ
DKEALKKQLP
AQNELIWNIK
GALLPCKECS
REISYLKKLK
LSNMKILTLG
SKKMEEVKAA
GEVVAPKGKS
HSAHVLEKGG
RVGTVIGSNK
LEIDYGQDEE
IDLQKMPLGK
PHDFGMKKPP
DVNYEKLKTD
REGESQRYKP
FGKGIYFADM
LPKGKHSVKG
VYDIAQVNLK

Figure 4.8. MALDI-TOF MS identification of DNA pull-down protein extracted from
αT3-1 cells treated with vehicle. A shows protein hits from mouse sequence in NCBI
database (147782 sequences). Protein hits are listed in descending order of MOWSE
score. B shows highest matching protein based on MOWSE score, molecular mass, and
sequence coverage.
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A
Database : NCBInr 20100601 (11112683 sequences; 3786819628 residues)
Taxonomy : Mus. (147782 sequences)
Timestamp : 10 Jun 2010 at 21:11:58 GMT
Protein hits: gi|20806109 poly [ADP-ribose] polymerase 1 [Mus musculus]
gi|4159806
type II keratin subunit protein [Mus musculus]
gi|12859782 unnamed protein product [Mus musculus]
gi|387397
epidermal keratin subunit I [Mus musculus]
gi|9910294
keratin, type II cytoskeletal 71 [Mus musculus]
gi|741022
keratin 15
gi|46485130 TPA: TPA_exp: keratin Kb40 [Mus musculus]
gi|52789
unnamed protein product [Mus musculus]
gi|22164776 keratin, type II cytoskeletal 79 [Mus musculus]
gi|13272554 cytokeratin KRT2-6HF [Mus musculus]
gi|85701680 keratin, type II cytoskeletal 2 oral [Mus musculus]
gi|398168
keratin 2 epidermis [Mus musculus]
gi|7106335
keratin, type I cytoskeletal 17 [Mus musculus]

B
Match to: gi|20806109; Score: 1478; poly [ADP-ribose] polymerase 1 [Mus
musculus]
Nominal mass (Mr): 113506; Calculated pI value: 9.06
Taxonomy: Mus musculus
Sequence Coverage: 43%
Matched peptides shown in Bold
1
51
101
151
201
251
301
351
401
451
501
551
601
651
701
751
801
851
901
951
1001

MAEASERLYR
WYHFSCFWKV
GSGGKAEKTL
LGMIDRWYHP
AIKNEGKRKG
DELKKACSTN
GQLVFKSDAY
VKKQDRIFPP
KLSQNKDEAK
NVRVVCEDFL
AAPSKKSKGA
KVFSATLGLV
LEQMPSKEDA
AVKKLTVKPG
LSRRQIQAAY
LLNNADSVQA
IKVVDRDSEE
FRQLHNRRLL
VSKSANYCHT
LGKTTPDPSA
YLLKLKFNFK

VEYAKSGRAS
GHSIRQPDVE
GDFLAEYAKS
TCFVKKRDEL
DEVDGTDEVA
DLKELLIFNQ
YCTGDVTAWT
ESSAPAPLAL
AVIEKLGGKL
QDVSASTKSL
VKEEGVNKSE
DIVKGTNSYY
VEHFMKLYEE
TKSKLPKPVQ
SILSEVQQAV
KVEMLDNLLD
AEVIRKYVKN
WHGSRTTNFA
SQGDPIGLIL
SITLEGVEVP
TSLW

CKKCSESIPK
VDGFSELRWD
NRSMCKGCLE
GFRPEYSASQ
KKKSKKGKDK
QQVPSGESAI
KCMVKTQNPS
PLSVTSAPTA
TGSANKASLC
QELLSAHSLS
KRMKLTLKGG
KLQLLEDDKE
KTGNAWHSKN
ELVGMIFDVE
SQGSSESQIL
IEVAYSLLRG
THATTHNAYD
GILSQGLRIA
LGEVALGNMY
LGTGIPSGVN

DSLRMAIMVQ
DQQKVKKTAE
KIEKGQMRLS
LKGFSLLSAE
DSSKLEKALK
LDRVADGMAF
RKEWVTPKEF
VNSSAPADKP
ISTKKEVEKM
SWGAEVKAEP
AAVDPDSGLE
SRYWIFRSWG
FTKYPKKFYP
SMKKALVEYE
DLSNRFYTLI
GSDDSSKDPI
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SPMFDGKVPH
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IDLQKMPLGK
PHDFGMKKPP
DVNYEKLKTD
REGESQRYKP
FGKGIYFADM
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Figure 4.9. MALDI-TOF MS identification of DNA pull-down protein extracted from
αT3-1 cells treated with 100 nM dexamesathone. A shows protein hits from mouse
sequence in NCBI database (147782 sequences). Protein hits are listed in descending
order of MOWSE score. B shows highest matching protein based on MOWSE score,
molecular mass, and sequence coverage.
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To confirm PARP-1 binding and demonstrate interaction between GR and PARP1 to the -290/-270 region of the porcine GnRHR promoter, EMSAs were performed with
the addition of an antiserum directed against PARP-1 and GR to the specific binding
complex for a probe spanning -290/-270 region of the promoter. Addition of antibodies
against GR and PARP-1 generated a supershift with nuclear extracts of αT3-1 cells
treated with both vehicle or 100 nM dexamethasone (Figure 4.6). Interestingly, the
combination of antibodies specific for GR and PARP-1 abrogated the specific binding
complex both control and 100 nM dexamethasone treated cells. Thus, this result indicates
GR and PARP-1 copoerate to regulate glucocorticoid responsiveness of the porcine
GnRHR gene.
The glucocorticoid receptor (GR) is phosphorylated via ERK1/2 and p38
MAPK signaling pathways in αT3-1 cells.

Ligand binding to GR leads to

phosphorylation of GR, stimulation GR signaling and glucocorticoid responsiveness of a
target cell.

In order to examine which signaling pathway(s) were responsible for

phosphorylation of GR underlying glucocorticoid responsiveness of the porcine GnRHR
promoter, we transiently transfected αT3-1 cells with the full-length porcine GnRHR
promoter and then treated with 100 nM dexamethasone in the presence or absence of
SB202190, a p38 MAPK inhibitor, or U0126, a MEK1/2 inhibitor (Figure 4.10). Both
inhibitors reduced dexamethasone-induced luciferase activity of the porcine GnRHR
promoter. However, western blot results showed no changes of the phosphorylation of
ERK and p38 MAPK during dexamethasone treatment (Figure 4.11). Interestingly, both
ERK and p38 MAPK were already phosphorylated before dex treatment. This result
indicates that ERK and p38 MAPK are not phosphorylated by GR signaling but they
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phosphorylate GR to activate the GR translocation. This result is also consistent with
Kotitschke et. al. (2009). Next, to investigate the relevance of the PKC or PKA signaling
pathways in glucocorticoid responsiveness of the porcine GnRHR promoter, we
transiently transfected αT3 cells with the full-length porcine GnRHR promoter and then
treated αT3 cells with 100 nM dexamethasone and either a PKC inhibitor (GF109203X),
a PKA inhibitor (SQ22536), or combination of both (Figure 4.12). Neither inhibitor
decreased dexamethasone-stimulated luciferase activity of the promoter.

Therefore,

protein kinase A (PKA) and C (PKC) do not participate in GR activation and the
glucocorticoid responsiveness of the porcine GnRHR gene, whereas p38 MAPK and
ERK1/2 regulate glucocorticoid-induced promoter activity of the porcine GnRHR gene
via GR phosphorylation.
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Figure 4.10. Signaling pathways underlying glucocorticoid responsiveness of the porcine
GnRHR promoter. αT3-1 cells were transiently transfected with the full length porcine
GnRHR promoter. After 12 h, cells were treated with either SB202190 (p38 MAPK
inhibitor) or U1206 (MEK1/2 inhibitor) 15 min prior to 100 nM dexamethasone
treatment. Both inhibitors decreased dexamethasone-induced promoter activity.
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Figure 4.11. Phosphorylation of ERK and p38 MAPK during 100 nM dexamethasone
treatment. Western blot results showed no changes of the phosphorylation of ERK and
p38 MAPK during dexamethasone treatment. Interestingly, both ERK and p38 MAPK
were already phosphorylated before dex treatment.
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Figure 4.12. Signaling pathways underlying glucocorticoid responsiveness of the porcine
GnRHR promoter. Cells were transfected and treated with either GF109203X (PKC
inhibitor) or SQ22536 (PKA inhibitor) as shown in A. Both inhibitors had no effect on
dexamethasone-induced promoter activity. Bars with different superscripts differ (P <
0.05).
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Discussion

Many studies have shown that hormones, including GnRH, estradiol, and
progesterone induced responsiveness of the GnRHR gene. For example, GnRH can upor down-regulate the numbers of its receptor in the pituitary (McArdle et al., 1987;
Uemura et al., 1992), and regulate GnRHR mRNA levels in pituitary cells of the rat
(Kaiser et al., 1993; Bauer-Dantoin et al., 1995), sheep (Turzillo et al., 1995), and cow
(Vizcarra et al., 1997). Estradiol treatment of rat pituitary primary cultures can increase
(long-term exposure) or decrease (short-term exposure) the number of GnRHRs (Menon
et al., 1985; Emons et al., 1995). In the ewe, exogenous estradiol consistently increased
the number of GnRHRs both in vivo (Kirkpatrick et al., 1998) and in vitro (Gregg et al.,
1990; Laws et al., 1990). On the other hand, administration of progesterone decreased
GnRHR mRNA levels in the ovine pituitary (Bauer-Dantoin et al., 1995) as well as
primary pituitary cultures from the sheep (Wu et al., 1994).

In addition to these

hormones, glucocorticoids have also been implicated in the physiological regulation of
GnRH and its receptor. Chandran et al. (1994) reported that glucocorticoids act directly
at the hypothalamus to suppress GnRH synthesis.

Dubey and Plant (1985) also

demonstrated that glucocorticoids reduced the activity of the GnRH pulse-generating
center within the hypothalamus. Similarly, in the pituitary, glucocorticoids decreased
GnRH responsiveness of the gonadotropes.

Although most studies have reported

inhibitory effects of glucocorticoids on the production of the GnRHR, conflicting reports
exist as others have demonstrated stimulatory effects. For example, glucocorticoids
increased responsiveness of the mouse GnRHR gene (Maya-Núñez et al., 2003,
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Kotitschke et al., 2009), GnRHR mRNA levels (5-fold; Turgeon et al., 1996), and
gonadotropin subunit gene expression as well as gonadotropin secretion (Rosen et al.,
1991). Thus, the mechanisms underlying glucocorticoid responsiveness of the GnRHR
gene remain to be uncovered.
In this present study, we determined dexamethasone responsiveness of the porcine
GnRHR gene using transient transfections in mouse gonadotrope-derived αT3-1 cells.
Further, we investigated the signaling mechanisms underlying the dexamethasone
responsiveness of the porcine GnRHR gene. Our results showed that dexamethasone
activated the porcine GnRHR gene in a dose-dependent manner (Figure 4.1). Moreover,
we reported that the optimal dexamethasone treatment was 100 nM and this response was
mediated by GR and its translocation to the nucleus (Figure 4.2 and 4.3).

Our

observation that dexamethasone increased GnRHR promoter activity is consistent with
previous reports.

Maya-Núñez and coworkers (2003) examined glucocorticoid

responsiveness of the mouse GnRHR gene promoter. In this study, dexamethasone
activated the mouse GnRHR promoter in rat pituitary adenoma-derived GGH3 cells and
this response was blocked by a glucocorticoid antagonist (RU 486). Progressive 5’deletion study identified a putative glucocorticoid response element within the region 331/-255 of the mouse GnRHR gene promoter and point mutation study revealed AP-1 as
the glucocorticoid response element. Further, they determined that this AP-1 element
was directly associated with the c-Jun binding protein to increase dexamethasone induced
gene expression of mouse GnRHR. Like Maya-Núñez et al. (2003), we also utilized RU
486 as a glucocorticoid antagonist to determine the specificity of the dexamethasone
response by GR. RU 486, however, was the prototype of antiprogestins which have
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potential uses for contraception and for treatment of hormone-related pathological
conditions such as breast cancer, endometriosis, and leiomyomata (Attardi et al., 2004).
Moreover, the RU 486 and PR complex still binds to progesterone responsive elements
(PREs) at the target gene, but this does not induce gene activation due to conformational
changes of the complex (Baulieu, 1991; Kloosterboer et al., 1994). Therefore, in order to
confirm the specificity of the dexamethasone response mediated by not PR but GR, we
utilized a new potent antiprogestagen, Org 31710 (Figure 4.2). It has been reported that
Org 31710 had almost similar to RU 486 in relative binding affinity to the cytoplasmic
PR, and Org 31710, however, had above 30 fold lower binding to the GR than RU 486
(Kloosterboer et al., 1994). They also suggested that in vivo, Org 31710 appear to be 10
fold more selective in antiprogestagenic effect than RU 486, which is mainly due to its
low antiglucocorticoid activity. In our experiments, Org 31710 functioned well as a
potent antiprogestagen with no effect on dexamethasone induced porcine GnRHR gene
promoter activity via GR.

Interesting result in that 1 nM Org 31710 abolished

dexamethasone induced the promoter activity can be explained by its binding affinity to
GR. It is because increasing amount of Org 31710 can increase binding to GR and
reduce GR function even though it has 30 times less binding affinity than RU 486. This
was confirmed by that 10 times more Org 31710 was required than RU 486 to remove
dexamethasone stimulated promoter activity (Figure 4.1 and 4.2).
It has been well established that the GR resides in the cytoplasm in an unliganded
state and the presence of glucocorticoid results in cytoplasmic liganded GR translocation
to nucleus (Wikstrom et al., 1987; Picard and Yamamoto, 1987). Our western blot
analysis result supported this statement, showing predominant appearance of GR protein
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in the nucleus than in the cytoplasm after dexamethasone treatment (Figure 4.3). In the
absence of glucocorticoid, unliganded GR exists as an oligomer associated with the
chaperone complex including hsp90, hsp70, p23 and one hsp90-binding tetratricopeptide
repeat (TPR) protein in the cytoplasm (Pratt et al., 2004). hsp90 binds to the GR ligandbinding domain, which leads to open the ligand binding cleft and maintains the GR in a
conformation suitable for ligand-binding (Picard et al., 1990; Pratt et al., 2006). The
hsp90 chaperone machinery is also required for the translocation of the ligand-GR
complex into the nucleus (Pratt et al., 2006). Upon ligand-binding, the GR undergoes a
conformational change and hyperphosphorylation, and subsequently move within the
nucleus to their sites of action (Avenant et al., 2010; Czar et al., 1997). Translocation of
ligand-GR complex is mediated by nuclear localization signal (NLS) sequences in the
receptors themselves (Picard and Yamamoto, 1987) and bidirectional shuttling of
receptors into and out of the nucleus occurs constantly (Guichon-Mantel et. al., 1991;
Chandran and DeFranco, 1992; Madan and DeFranco, 1993; Dauvois et al., 1993).
Studies of mechanisms on the nuclear localization of the cytoplasmic steroid receptors
have demonstrated two different mechanisms. The most efficient mechanism is rapid
with less than 5 min half-life and depends on the hsp90-FKBP52-based heterocomplex
(Davies et al., 2002; Galigniana et al., 2002; Gallo et al., 2007; Harrell et al., 2004;
Pilipuk et al., 2007). The alternative mechanism is hsp90 independent with about 40 to
60 min half-life, which allows the formation of degradasomes and the subsequent
targeting of the receptor to proteasomal degradation (Galigniana et al., 2004). In contrast
to the translocation of the receptor to the nucleus, GR cycles back very slowly to the
cytoplasm with 8 to 12 hour upon steroid withdrawal (Galigniana et al., 1998).

98
Once the nuclear localization of ligand-GR complex occurs, the active GR can
directly bind to either positive GREs that lead transcription activation or negative GREs
that direct transcription repression on DNA to regulate target gene expression (Lu and
Cidlowski, 2006). In addition, the active GR interacts with transcription factors to either
enhance or repress the transcription of target genes by interfering with or modifying the
actions of the GR partners (Lu and Cidlowski, 2006; Lu and Cidlowski, 2004). The GR
can recruit a variety of proteins such as co-activators, co-repressors and chromatin
remodeling complexes, depending on the cell type and promoter context to result in
transactivation or transrepression (McKenna et al., 1999; Lu and Cidlowski, 2006;
Avenant et al., 2010). Therefore, to localize the GRE(s) within the porcine GnRHR
promoter that is responsible for glucocorticoid responsiveness via GR-mediated
transcriptional activation, we performed transfection assays with reporter vector
containing sequential deletion of 5’ flanking sequences for the porcine GnRHR gene
(Figure 4.4). These data suggested that the regions -320 to -270 are responsible for
dexamethasone-induced porcine GnRHR activity and there is/are important element(s),
GRE(s), within the regions.

Further investigations by EMSA revealed more precise

location of GRE, showing increased binding to the nuclear extracts from dexamethasone
treated αT3-1 cells compared to vehicle (Figure 4.6) as well as by transfection assays
(Figure 4.5). Interestingly, the result of EMSA from the binding competition based on
sequence analysis showed that instead of GR, ER bound to GRE (Figure 4.6). However,
supershift assay using ER antibody did not generate ER-antibody binding complex with
the probe containing -290 to -270. Taken together, our findings suggested that the
porcine GnRHR promoter does not have GRE, and the GR, thus, does not bind directly to
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the promoter but rather via GR-protein interaction or nongenomic signaling without GRDNA binding to regulate dexamethasone-stimulated responsiveness on the porcine
GnRHR gene. In addition to GR, ER and PR, sequence analysis of the regions -290 to 270 has indicated several putative transcription factor binding sites including STAT,
SMAD, COUP-TF, GATA, and Pit-1.

Unfortunately, we were unable to identify

protein(s) comprising the specific binding complex following addition of antibodies to
EMSAs (data not shown). We assumed that it is because limitation of sequence analysis
database, TRANSFAC® public 6.0 which provides data on transcription factors, their
experimentally-proven binding sites, consensus binding sequences and regulated genes in
eukaryotes. Thus, we directly isolated transcription factor(s) from the complex with the
regions -290 to -270 of the promoter by DNA-protein pull-down assay and SDS-PAGE,
and then identified the protein(s) using mass spectrometry. Results from the experiments
showed a novel transcription factor, PARP-1 which interacts with GR in αT3-1 cells
(Figure 4.8 and 4.9) and were confirmed with super shift assay using the specific
antibody to PARP-1 (Figure 4.6). Our interesting finding of GR-PARP-1 interaction was
supported by Muthumani et al. (2006). They reported that the 96-amino acid viral protein
R (Vpr) of HIV-1, which functions as a vital accessory gene by regulating various
cellular functions, uses the GR pathway as a recruitment vehicle for the NF-κB coactivating protein, PARP-1. They also mentioned that the interaction of Vpr with GR
may lead to conformational changes within the complex to expose binding sites for the
PARP-1 but dexamethasone treatment, however, is insufficient to recruit PARP-1 and
interact with GR. Although their indication that the GR association with PARP-1 is a
gain of function which is solely attributed to HIV-1 Vpr is different with our observation,
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we believe that we are the first group to prove direct interaction of GR with PARP-1 on
the porcine GnRHR gene promoter and it is cell specific event. However, it still remains
to be determined to understand the details of this regulation in vitro and in vivo.
PARP is a nuclear enzyme that catalyzes the transfer of ADP-ribose units utilizing
NAD+ as a substrate to various nuclear proteins (de Murcia et al., 1994; Lindahl et al.,
1995). PARP-1 is the most abundant and ubiquitous member of this family including
PARP-1, -2, -3, v-PARP, and tankyrase (Smith et al., 1998; Ame et al., 1999; Johansson,
1999; Kickhoefer et al., 1999). PARP-1 has been implicated in several catalytic activities
and biological processes, including DNA replication (Simbulan-Rosenthal et al., 1998),
HIV replication (Cole et al., 1991), DNA repair (de Murcia et al., 1994), carcinogenesis
(Kun, 1998; Bauer et al., 1995), Chromatin remodeling (Gottschalk et al., 2009; Ahel et
al., 2009), cell proliferation (Sakamaki et al., 2009; Pagano et al., 2007), and apoptosis
(Boulares et al., 1999; Alano et al., 2010). Further, several reports suggested a novel role
for PARP-1 as a coactivator or repressor of transcription factors such as AP-1, SP-1, Oct1, YY-1, and STAT-1 that mediate the stress/inflammation response (Nie et al., 1998;
Oei et al., 1997; Ha et al., 2002). Consistent with these reports, in the present study, we
determined that PARP-1 played a role as a coactivator showing that the anti-PARP-1
antibody did not completely abolish the specific DNA-protein complex in the supershift
assay, thus indicating that other transcription factors or coregulatory proteins may
contribute to the complexes with PARP-1. Therefore, we postulate that PARP-1 function
as a member of the transcription machinery with GR to regulate the porcine GnRHR gene
expression following dexamethasone treatment.
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Although steroid hormones act as the primary signal in activating the receptor’s
transcriptional regulatory functions, the phosphorylation of the receptors is also a
mechanism to positively or negatively modulate receptor-mediated transcriptional
responses (Ismaili and Garabedian, 2004). Unliganded GR is phosphorylated and in the
presence

of

glucocorticoid,

GR

becomes

hyperphosphorylated

by

additional

phosphorylation to result in translocation of ligand-binding GR to nucleus and
transactivation or transrepression in gene expression (Wang et al., 2002; McKenna et al.,
1999). As a first step toward the characterization of the signaling mechanisms effecting
dexamethasone-induced translocation and transcriptional regulation of GR, we
investigated the potential roles of MAPKs. Our findings suggested that ERK1/2 and p38
MAPK are responsible for dexamethasone induced promoter activity via GR
phosphorylation (Figure 4.10 and 4.11). Kurl and Jacob (1984) reported direct evidence
for GR phosphorylation showing incubation of GR from rat liver cytosol with γ 32P-ATP
and Mg2+ resulted in transfer of the radiolabeled phosphate to the GR. Since that, many
studies have been reported on ligand-dependent GR phosphorylation in vivo (Ortí et al.,
1989; Dalman et al., 1988) and Kaul et al. (2002) suggested the involvement of
endogenous protein kinases during the phosphorylation event of GR from rat liver
cytosol. MAPKs respond to a variety of cellular stimuli such as growth factors, stress
events, cytokines, and mitogens and, when they are activated, mediate diverse cellular
processes including gene transcription, chromatin remodeling, apoptosis, and
inflammation (Pearson et al., 2001). Glucocorticoid-mediated GR phosphorylation via
MAPKs has been studied intensively in many cells and it has been suggested that this
event is dependent on multiple kinases in a cell-, promoter-, and glucocorticoid-dose-
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dependent manner (Ismaili et al., 2004; Chen et al., 2008; Webster et al., 1997; Kino et
al., 2007). For example, JNK and ERK pathway have been involved in phosphorylation
of the rat GR at Ser-246 or human GR at Ser-211 (equivalent to mouse GR Ser-234) as
well as in dex-mediated transcription, showing direct role in GR phosphorylation and
transcriptional regulation (Krstic et al., 1997; Rogatsky et al., 1998; Miller et al., 2007).
In addition, Kotitschke et al. (2009) showed combinations of JNK, ERK, and p38 MAPK
inhibitors decreased dex-induced phosphorylation of the endogenous mouse GR at Ser234 and suggested a complex interplay between MAPKs and possibly other kinases in
response to dex treatment to modulate mouse GR phosphorylation and transcription in
LβT2 cells.
In conclusion, we demonstrated glucocorticoid responsiveness of the porcine
GnRHR gene in αT3-1 cells and identified PARP-1 as a transcription factor responsible
for this responsiveness. In addition, we determined that this transcriptional regulation
was mediated by ERK1/2 and p38 MAPK pathway, phosphorylating dex-bound GR.
Finally, we suggested working model for the mechanisms underlying glucocorticoid
regulation of the porcine GnRHR gene (Figure 4.13) Once glucocorticoid binds to GR in
the cytoplasm, ERK and p38 MAPK phosphorylate and activate GR to activate, releasing
heat shock protein (HSP). Phosphorylated, ligand-bound GRs are translocated to the
nucleus and recruit poly (ADP-ribose) polymerase-1 (PARP-1) to bind to the
glucocorticoid response element, activating the porcine GnRHR gene.
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Figure 4.13. Working model for the mechanisms underlying glucocorticoid regulation of
the porcine GnRHR gene. Once glucocorticoid binds to GR in the cytoplasm, ERK and
p38 MAPK phosphorylate and activate GR to activate, releasing heat shock protein
(HSP). Phosphorylated, ligand-bound GRs are translocated to the nucleus and recruit
poly (ADP-ribose) polymerase-1 (PARP-1) to bind to the glucocorticoid response
element, activating the porcine GnRHR gene.
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Appendix I

In addition to glucocorticoid responsiveness, I determined progesterone
responsiveness of the porcine GnRHR gene. The promoter showed increased
progesterone-induced activity in a dose dependent manner and decreased activity by
mifepristone. Whereas dexamethasone-stimulated promoter activity was blocked with
100Pm mifepristone, progesterone-induced activity required 10,000 times more
antagonist. This result also demonstrated further confirmation that dexamethasone
responsiveness of the porcine GnRHR gene is mediated by GR, not PR.
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Appendix II

Our laboratory investigated breed differences on the porcine GnRH receptor
promoters of Chinese Meishan, UNL Index, White crossbred line because each breed has
different ovulation rate and litter size. Transfection study showed that Meishan promoter
was most highly expressed in aT3 cells compare to other two breeds. In addition, we
have identified polymorphism among the breeds. Therefore, because of these breed
differences in cell specific expression, I examined breed differences on the
glucocorticoids responsiveness. Reporter constucts containing either the Control, Index
or Meishan GnRHR gene promoter responded equally (about 2-fold) to 100 nM
dexamethasone treatment.
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Appendix III

In this study, I determined two cell specific expression factors binding to the
porcne GnRHR gene promoter. Previously, our lab found 2 SF-1 site located -1760/1753 and -179/-171. I identified another SF-1 located between -315 and -307, and RXRα
and β between -279 and -274. Mutation of SF-1 site decreased basal expression of the
porcine GnRHR gene about 30%, and however, mutation of RXR α and β site completely
block the promoter activity. In addition, I also determined that there is a repressor
between -306 and -301. Mutation of this site increased basal expression of the receptor
gene about 17-fold.
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